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Circadian rhythms are self-autonomous endogenous clocks synchronized with the rotation
of the Earth. With the Earth’s rotation and revolution on its axis, the internal clock undergoes
oscillation in the period of ~24 hour and governs day to day activities in most organisms. In
humans, it regulates the day to day physiological activities. Today’s modern lifestyle has an impact
on health: shift work, jet lag, and irregular eating habits contribute to the misalignment of the
endogenous circadian oscillator, thereby, increasing the risk of many metabolic disorders including
diabetes, irregular blood pressure, sleep disorders, obesity, depression, and cancer. The primary
goal of this research is to design and synthesize therapeutic circadian clock modulators to target
clock-related dysfunctions.
This dissertation focusses on designing a library of small molecules which can act on core
circadian rhythm proteins. More specifically, the goal is to synthesize different analogs to target
cryptochrome. Cryptochrome is an integral part of the mammalian core circadian system and
regulates the process of gluconeogenesis, therefore it has been identified as a potential target for
type II diabetes. A carbazole scaffold (KL001) was shown to bind at the active site of
cryptochrome resulting in a shift in circadian period, and modulation of gluconeogenesis. Herein,
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a library of the small molecules is synthesized and evaluated based on the structure-activity
relationship of KL001.
Just like mammals, most living organisms have developed an endogenous circadian clock.
In the latter part of the dissertation, the focus shifts to study of the crucial circadian rhythm proteins
of plants. In plants, Light Oxygen Voltage (LOV) domain proteins play an essential role in
photoperiodic growth events. LOV domains employ small molecule chemistry to sense blue light
in the environment and facilitate plants acclimating their surroundings. In Arabidopsis, the
Zeitlupe (ZTL), flavin binding kelch repeat F-box1 (FKF1) and LOV Kelch protein-2 (LKP2)
work in concert to measure the day length and to determine flowering time and regulate other
circadian processes. Specifically, the focus will be to study the thermal kinetics of LKP2 protein
of Arabidopsis thaliana. Furthermore, this study is extended to examine the thermal kinetics of
LKP2 protein in an agriculturally important crop Brassica rapa. Finally, a crystal structure of the
cryptochrome-like algal protein OtCPF1 is discussed.
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CHAPTER 1
CIRCADIAN RHYTHM: NEW AVENUES FOR THE DRUG DISCOVERY

A famous dictum by Benjamin Franklin, “Early to bed, early to rise” is based on the theory
that night is for sleeping while waking up should take place with the sunrise. Indeed, time plays a
vital role in day to day life. A sudden shift in the routine can make us dysfunctional. Jet-lag is
inevitable while traveling to the different time-zones. It is because of an internal circadian
(biological) clock which dictates the daily physiological behaviors. This chapter provides a brief
overview of the mammalian circadian rhythm, and asks a fundamental question; How does it
govern our daily behavior? Are there any diseases associated? And if yes, then what efforts are
being made to discover clock-based therapies to improve the human physiology.
1.1 Introduction
The key to life existing on the Earth lies in its ability to adapt to the environment.
Organisms living in the different geographical conditions have adapted to distinct environment
necessary for the survival. Essential to such adaptation and survival is the ability to synchronize
daily events to the diurnal solar cycle. To adapt to such changes, most living organisms on the
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Earth have evolved an internal biological clock that anticipates the fluctuation in day (light) and
night (dark) pattern and optimizes the organisms’ physiology and behavior1. This intrinsically
generated biological clock is known as a circadian rhythm.
Circadian rhythms are self-autonomous endogenous clocks synchronized with the rotation
of the Earth. Circadian clocks are defined by three requirements 1) They must demonstrate ~24hour period that is consistent with the Earth’s rotation and revolution on its axis and governs day
to day activities in the organisms1-5. 2) The circadian period must be temperature independent
(temperature compensated). 3) Despite the rhythm being synchronized with the Earth rotation, it
must not depend on the sunlight (or any other exogenous cue) for its sustainability; indeed
circadian rhythms still persist even in the dark hence they are endogenous free running rhythms of
approximately 24-hours5-7.
The internal biological clock anticipates dusk and dawn and prepares the organism to
harness the maximum benefits of each aspect of the day/night cycle, while mitigating dangers
associated with the damaging effects of the sun’s rays. Circadian rhythms are ubiquitous and are
found both in prokaryotes and eukaryotes. Amongst prokaryotes, only cyanobacteria have been
shown to have a robust circadian rhythm; which is likely associated with their photosynthetic
abilities that necessitate temporal regulation of energy collection and use8,9. In eukaryotes such as
plants, their sessile nature requires coordination of their growth and development with diurnal
changes in environmental conditions. Hence, plants have developed an intricate array of several
photoreceptors which work in a circadian fashion to assist plants in adjusting to the surroundings.
These photoreceptors sense a broad spectrum of light which facilitates acclimation to the
surrounding environment and regulates their growth and development10-11. Although mammals are
not directly dependent on light for metabolic needs or growth and development, mammals retain
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analogous circadian networks to temporally segregate metabolic pathways. Hence in mammals the
circadian clock plays a vital role in governing daily metabolic activities like a sleep-wake cycle,
hormone secretion and diverse aspects of human physiology.
Hence, it is not wrong to say circadian rhythm is a “timekeeping” mechanism present in
nearly all the organisms residing on the Earth. Therefore, it is imperative to study the molecular
basis of circadian clocks to provide a deeper insight into the nature of biological timekeeping and
the intricate mechanisms necessary to coordinate and synchronize such a clock with environmental
factors. In this chapter, we go in depth to understand how the clock works through the
implementation of a negative feed-back loop. Further, we will develop a brief history of the
circadian rhythm research. Finally, this chapter will delve into the specific biochemical pathways
that maintain mammalian circadian rhythm and discuss how the core circadian protein
cryptochrome plays a vital role in human disease including in regulating diabetes.
1.2 Characteristic and Molecular basis of the circadian clock
The core component of a basic circadian clock consists of an input pathway, which
perceives the stimulus from the environment and transmits the environmental signal to a central
oscillator. The central oscillator, in turn, entrains the signal and maintains ~24-hour endogenous
rhythm that modulates diurnal regulation of desired outputs such as gene expression. Notably,
some output feedback into the core oscillator rhythmically suppresses gene expression. As a result,
the next cycle starts, and the process continues. This process is called feedback inhibition and is a
central component of all clock networks5,6,12-13.
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Figure 1: An abstract view of circadian rhythm: The input signal activates the pacemaker of
the biological clock, which in turn, drives the expression in a rhythmic fashion

All circadian processes follow the same pathway in all the organisms residing on the Earth,
e.g. plants, fungi and animals. However, the number of proteins participating differs, depending
upon the complexity of an organism. For these reasons, much of the initial circadian rhythm
research focused on understanding how the central oscillator is able to maintain a temperature
compensated 24-hour period through regulation of a negative feedback loop.

1.2.1 The feedback loop

“What goes up, must come down, spinning wheel got to go around.”
At the core molecular level, circadian rhythm involves successive gene expression and
repression through a transcription and translation feedback loop (TTFL). The process is wellcoordinated and orchestrated like a musical rhythm. Just like a wall clock, the feedback loop
consists of two elements: a positive limb (or element) which drives the expression of all genes
under control of the circadian clock and the negative limb (or element) that inhibits gene
expression leading the path for a new cycle to begin. Importantly, the TTFL and feedback loops
4

do not operate in isolation. Coincident with transcription/translation numerous post translational
regulation events modulate the stability and function of key clock proteins. For instance, a set of
ubiquitin ligase protein maintains the periodicity by subsequently degrading the repressor proteins,
such that a new cycle can get started with the 24 hours periodicity and thereby improving the
robustness of the circadian network and facilitating adaptation in the presence of diverse
environmental signals. By this process, the internal clock is synchronized with environmental
signals allowing an organism to both maintain a 24-hour period (TTFL), but also adapt to
environmental change or pressures through peripheral loops that involve post-translational
pathways. Without this complicated interplay between the core TTFL and peripheral loops, we
would not be able to adapt to different time zones and overcome jet lag14-17.

Figure 2: General mechanism of autoregulatory feedback inhibition in the basic circadian
clock: The positive element drives the expression of the negative element, which in-turn inhibits
action of the positive element. (Adapted from ref: 15).
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1.2.2 Important clock parameters

The autoregulatory feedback inhibition (circadian rhythm) of gene regulation can be tested
in a laboratory. Experiments are typically done by measuring gene expression, behavior cues or
epigenetic modification over a multiple-day time course. These time courses are conducted on
samples after they have been synchronized (entrained) by the environmental stimuli such as:
alternating light and dark cycle or drug or small molecule introduction. In conducting such studies,
there are specific terms used during these experimental approaches which are unique to the field.
We explain these terms below:
Zeitgeber time (ZT): is the German term which means “time giver.” It is a standard notation of 24hour phase, where ZT = 0 means dawn (or beginning of the experiment) and ZT = 12 is termed as
the beginning of the dark phase or night.
Period: Period is the time taken to finish one cycle. It can be measured as the distance between
two consecutive peaks or troughs (Fig 3). To be considered circadian, the period must remain
approximately 24-hours regardless of temperature.
Phase: Phase is the time of day at which a particular event occurs. For instance, if an element
within the circadian rhythm demonstrates a peak at 12 hours after ZT = 0 (dawn), then the phase
will be 12 hours10.
Amplitude: Amplitude of the rhythm is the one half of the peak to trough distance10.
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Figure 3: Important clock parameters: Period is the time taken to complete one cycle. Phase is
the time at a particular event. Amplitude is half of the distance between a peak and trough

1.3 Discovery of circadian rhythm to chronotherapy: Historical perspective
Circadian rhythms were said to be first observed by the Greek geographer Androsthenes at
the time of Alexander the Great in 4th century B.C when he noticed daily leaf movements of the
tamarind tree, Tamarindus indicus on the islands of Tylos (now Bahrein) in the Persian Gulf.
Despite such observations, it was another two millennia until the first experimental studies on
circadian rhythms were conducted. They were conducted by the French astronomer Jean-Jacques
d’Ortous de Mairan, who reported leaf movements of the sensitive Mimosa pudica plant
(commonly known as “touch me not” plant) were persistent even in the constant darkness, which
led him to conclude the rhythm to be endogenous and self-sustaining16. He later extended his
research to the human patients with sleep defects. After that, in 1729 he published the first paper
in circadian rhythm research. These experiments were not without controversy, and numerous
researchers tried to debunk or better understand how non-human species could measure time.
Research on circadian rhythms became more formalized in the 20th century. In 1950s Franz

7

Halberg coined the word “circadian” from the Latin word circa diem (about a day)1,19. Over the
last 100 years, identification of the molecular components of circadian clocks has attracted the
attention of both biochemists and chemists, who aimed to identify fundamental chemical and
biochemical components necessary to maintain biological clocks. These efforts have led to
substantial research aimed at unraveling how circadian rhythms dictate growth and development
in plants, to aid in crop production, and regulation of diverse aspects of human physiology as it
relates to disease phenotypes. Today it is a fast-growing field in biomedical research. Delightfully,
last year in 2017, the Nobel prize in physiology or medicine was awarded to Jeffery C. Hall,
Michael Rosbash and Michael W. Young for their discoveries of the molecular mechanism that
controls circadian rhythms.
1.4 Mammalian circadian rhythm
In mammals, the circadian clock plays pivotal roles in governing physiological and
metabolic processes like the sleep-wake cycle, hormone secretion, bowel movement, body
temperature, heart rate, and numerous others14, 15. Sudden changes in environmental inputs or
behavior thus leads to misalignment between the environment and physiological processes.
Diverse studies indicate that misalignment of the clock contributes to diverse disease phenotypes
and disorders. Importantly, circadian rhythms maintain the ability to reset the clock to re-entrain
endogenous rhythms in response to environmental inputs. For instance, traveling in another part
of the globe can lead to jet lag as the sleep-wake cycle gets disturbed. After some period, however,
we will naturally adapt to the new environment in response to metabolic cues (feeding) and
environmental light input. That is why one of the primary mechanisms recommended to deal with
the jet lag is to eat according the time of the day, and to look at the morning sun at the destination
and sleep according to the local day-night cycle.
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The circadian system of the mammals includes the input pathways, the central clock and,
the output. Light is the principal input; however, many output activities like food, temperature,
and physical activity reciprocally regulate the clock10, 13.

Figure 4: An abstract view of the mammalian circadian rhythm: The suprachiasmatic nucleus
(SCN) acts as a central oscillator. Light, the primary source of input activates the SCN, which in
turn relays the message to the peripheral organs. The clock also receives reciprocal effect from the
output such as food intake, temperature, and physical activity.

Light is the primary synchronizer of the biological clock. Light enters through the eyes,
gets perceived by the photoreceptor cells retinal ganglion located in the retina which then relays
the signal down through the optic nerve into the suprachiasmatic nucleus located in the
hypothalamus. The suprachiasmatic nucleus is the master regulator, also known as the pacemaker,
of the circadian clock in mammals20,22. Within each nucleus, there are about 20,000 neurons
capable of generating circadian rhythm in a self-autonomous manner. Subsequently, neural and
hormonal signals from the SCN entrains peripheral organs and tissues, synchronizing clocks in
nearly all cell types to the daily light-dark cycle. These peripheral organs and tissues then behave
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in a circadian fashion and participate in hormone secretion or other metabolic processes to maintain
homeostasis14, 16,18, 21-25.

Figure 5: A model of mammalian circadian rhythm system: Light activates the retinal ganglion
cells in eyes, the signal gets relayed to the suprachiasmatic nucleus (SCN), which acts as a
pacemaker of the circadian rhythm. The SCN then entrains signals to activate peripheral organs
via neural and endocrine pathways.

Because of the biological clock, the human body has a natural tendency to maintain
homeostasis. Disruption or misalignment of this behavior due to genetic manipulation or
environmental factors can lead to many physiological defects, such as sleep disorders,
cardiovascular disease, diabetes, obesity, cancer and other metabolic disorders. Consequently,
understanding the biochemical mechanisms dictating circadian clock function can open new
avenues in treating metabolic diseases or disorders at the genomic level and could have a
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substantial impact on human health13. This has paved the path of chronobiology or chronotherapy,
which means treating disorders by modulating the natural rhythm.
1.5 Molecular architecture of the mammalian circadian clock
In mammals, the canonical auto-regulatory transcription-translation feedback loop (TTFL)
consists of four core components: two transcription activators: CLOCK (Circadian Locomotor
output cycles kaput) and BMAL1 (Brain and Muscle Aryl-hydrocarbon receptor nuclear
translocator Like protein-1), and the transcriptional repressors, Periods (PERs) and Cryptochromes
(CRYs). In the core clock network transcription activators CLOCK and BMAL1 act as a positive
arm, whereas two of their target genes CRYs and PERs act as the repressor proteins to form the
negative limb of the TTFL. (Fig. 6 and 7)
Mechanistically, this is achieved by the transcription activator proteins CLOCK and
BMAL1, which heterodimerize to dictate the expression of clock-controlled genes (ccgs) via Ebox promoter elements. Upon accumulation, CRY and PER, in turn, heterodimerize in the
cytoplasm, translocate back to the nucleus to restrict their transcription by retarding CLOCK:
BMAL1 transcription. Currently, the mechanism by which CRY and PER alter CLOCK:BMAL1
expression is poorly understood, but it is believed to involve a large (megadalton) protein complex
recruiting numerous chromatin remodeling agents and transcriptional repressors to the promoter
elements. In conjunction with CLOCK:BMAL1 repression, CRY and PER are targeted for
degradation by ubiquitin-dependent proteolysis pathways. Degradation of CRY and PER relieves
the repression on CLOCK and BMAL1 gets relieved, and the process continues again with
approximately 24-hour periodicity1-5,15-18,21.
The ubiquitination mediated proteasomal degradation pathway in the negative feedback
loop plays a crucial role in maintaining a robust circadian oscillator. The ubiquitination process
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involves targeting protein for the 26S proteasomal degradation. At the post-transcriptional level,
SCF (Skp1-Cullin-F-box protein) complexes such as b-TrCP (beta-transducin repeat containing
E3 ubiquitin protein ligase) and FBXL3 (F-box and leucine-rich repeat protein 3) regulate the
stability of PER and CRY respectively and maintain the circadian rhythmicity24,25. More
specifically, kinases like casein kinase (CK1)26 and AMPK (adenosine monophosphate-activated
protein kinase) phosphorylate PER and CRY respectively. The respective F-box proteins then act
upon the phosphorylated proteins and form an E3 ubiquitin ligase complex. The tagged protein,
subsequently, undergoes degradation by the 26S proteasome complex. Another homolog F-box
protein of FBXL3, FBXL21 antagonizes the CRY degradation in the nucleus; thereby facilitates
the CRY turnover rate in the cytoplasm17, 21,28,31. Such competitive processes are common in
circadian networks and are believed to contribute to the robustness of the circadian oscillator.
Besides the core circadian oscillator, numerous feedback loops also participate in
modulating circadian function. One such secondary stabilization loop consists of nuclear hormone
receptors REV-ERB a/b and the antagonist-receptor ROR a/b/g29,30. Both REV-ERBs and ROR
(retinoic acid receptor related orphan receptors) work antagonistically and dictate the expression
of the core transcription factor BMAL131, 32. CLOCK/BMAL1 heterodimer, in turn, activates the
ROR and Rev-erb gene expression

21,33,34

. In this manner, peripheral loops can integrate diverse

pathways such as stress response, metabolism and cell-cycle repair into the core clock network
through secondary feedback loops. These secondary loops both facilitate cross-talk to diverse
pathways, but also contribute to the stability and robustness of the core oscillator.
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Figure 6: The molecular architecture of mammalian circadian rhythm: An autoregulatory
circadian feedback loop involves: the core loop consisting of the activators: CLOCK/BMAL1 and
the repressors: CRYs and PERs. The stabilizing loop involves Rev-erbα and ROR that regulates the
expression of BMAL1. CLOCK/BMAL1 heterodimer also regulates the downstream clockcontrolled genes (ccg). The stability of CRY and PER is regulated by the F-box proteins FBXL3
and b-TrCP respectively. The kinases, casein kinase 1(CK1) and AMPK phosphorylates PER and
CRY respectively to promote the ubiquitination via their respective F-Box proteins. The F-box
proteins tag PER and CRY for the degradation by the 26S proteasome complex. (Adapted from
Ref:33)

Importantly, all peripheral tissues and organs follow the same mechanism to couple
physiological and metabolic pathways to the circadian clock. All the core proteins involved in the
TTFL are crucial for the proper metabolic functioning. Indeed, several studies have shown
complete loss of metabolic pathways in mice lacking CLOCK and BMAL1, and CRY
functionalities34.
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To summarize, the circadian rhythm in mammals is generated by a set of hierarchal
interlocking genes that undergo self-autonomous transcription/translation feedback loops,
resulting in cascades of gene expression. To promote understanding, Fig 7 shows the simplified
version of the circadian loop.

Figure 7: Overall view of the circadian rhythm in mammals: Light activates the
suprachiasmatic nucleus located in the brain. The SCN then acts as a pacemaker of the circadian
rhythms and relays the signal down to the peripheral organs though neural or hormonal signals.
On the molecular level, the core circadian clock involves CLOCK and BMAL heterodimerize
rhythmically to drive the expression of CRY and PER, which in turn repress the expression of
CLOCK: BMAL through feedback inhibition.

1.6 Structures of the core circadian rhythm proteins
The circadian clock genes in mammals show rhythmic expression not only in the
suprachiasmatic nucleus (SCN) which is the pacemaker of the circadian clock generation but also
in the peripheral organs15. The core components of circadian clocks involve the hierarchy of genes
working in a rhythmic fashion. Central to this function are numerous competing and/or cooperative
protein:protein interaction networks that are modulated by post-translational modifications. To
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unravel the mechanism by which these protein:protein interaction networks modulate clock
function, and to delineate their signaling mechanisms, significant effort has been placed in
obtaining high-resolution structures and/or low resolution biophysical information on clock
proteins and functional protein complexes21,28. Recently, the high-resolution crystal structures of
several critical interacting proteins and proteins bound to the small molecule have become
available. These include a crystal structure of the CLOCK: BMAL1 complex35, the crystal
structures of isolated domains of all three PER proteins36,37, and crystal structures of multiple
functional forms of CRY proteins38-41. Table 1 summarizes the crystal structures of core clock
components known so far along with their PDB codes and the ligand bound.
Table 1: Crystal structure known for the core circadian proteins (adapted from Ref:28)

Protein

Domain

Ligand

PDB-ID

mCLOCK: mBMAL1
mPER1
mPER2
mPER3
mCry apo form
FAD bound mCRY
mCRY with FBXL3
mCRY with KL001
CRY2 in complex with per

bHLH
PAS AB
PAS AB
PAS AB
PHR-CC
PHR-CC
PHR-CC
PHR-CC
PHR-CC

DNA

4H1035
4DJ236
3GDI37
4DJ337
4K0R38
4I6G40
4I6J40
4MLP41
4CT039

FAD
FBXL3
KL001

These crystal structures provide a snapshot of a protein/interacting proteins and hence
reflect better insight into protein function and signaling mechanisms. For instance, the crystal
structure of CRY complexed with FBXL3 has revealed the mechanism by which the C-terminal
tail of the FBXL3 interacts with the CRY to initiate the degradation process40. In combination with
a crystal structure of the mCRY with its small molecule stabilizer (KL001), researchers were able
to delineate the mechanism by which small molecules can modulate clock function by attenuating
15

the stability of CRY proteins. Namely, the carbazole scaffold mimics the isoalloxazine ring of the
FAD to bind to the vacant FAD binding cleft in mammalian CRYs. In doing so, KL001
impersonates the FBXL3 tail thereby competitively binds to the CRY:FBXL3 interaction site and
delays the degradation process41. Thus, obtaining a high-resolution crystal structure not only assist
in understanding the signaling mechanism but also aid in designing small therapeutic
molecules8,9,21,44.
1.7 Resetting the clock: Chemical chronotherapy
Today’s modern lifestyle is impacting health and that ultimately is contributing to the
misalignment of the circadian oscillator with our normal day-night cycle. Shift work, frequent
travels to different time zones, and irregular eating habits contribute to misalignment of the internal
clock with the normal day night-cycle and are increasing the risk of many physiological disorders
like diabetes, sleep disorders, obesity, depression, and cancer6,23,50,51.
Recent research identifies significant health benefits that result from robust circadian
rhythms. As a result, medical researchers now focus on how circadian rhythms may modulate our
health or treatment practices. Initially, chronotherapy focused on identifying whether there were
specific times of day where drug or stimulus administration achieved the optimal therapeutic index
and pharmacokinetic profile. Interestingly, such approaches clearly indicated time-of-day specific
administration of elements as simple as blue (morning) and red (evening) light positively impacted
patients suffering from insomnia or depression. As a matter of fact, time-of-day specific light
treatments have been used as a drug-free remedy for the seasonal affective disorder (SAD)42,43.
Furthermore, extension of such time-of-day specific approaches to therapeutic intervention has
had significant impact on cancer patients, as they showed fewer side effects when the anti-cancer
drug gemcitabine was administered at 9 AM daily instead of 3 PM44. Delightfully, identification
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of the molecular architecture of the circadian rhythm proteins and their role in physiology has
emerged a new era in the field of chronobiology44,45,46. In particular, specific focus has been on
targeting core clock proteins directly, to deal with the negative consequences of misalignment
between endogenous circadian rhythms and the diurnal cycle.
Of late, small molecules are being exploited to manipulate the misaligned clock to prevent
or alleviate the clock related diseased conditions. Additionally, small synthetic drug-like molecules
bestow great potential to not only understand the function of the molecular clock system but also
can be used to target the diseases associated with the clock dysfunction. The approach anticipates
modulating the endogenous biological rhythm which can potentially “reset the clock” and
hopefully can treat physiological or metabolic pathologies13,34,45.
1.7.1 Circadian rhythm and drug intervention

Different clock elements (discussed earlier in the section 1.5) have been shown to impart
pathological disorders in mutant mice; implying, each component of the mammalian circadian
clock system has a crucial function. For instance, CLOCK mutant mice were found to be
hyperglycemic and obese whereas BMAL1 deficit mice showed decreased body weight and
infertile6,16,20,32. Additional physiological defects resulting from clock genotypes are outlined in
the table below.
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Table 2: Summary of the diseases associated with the mutation of different core clock elements

Mutant

Physiological Disorder

CLOCK

REV ERB

Altered sleep pattern, hyperglycemia, diet
induced obesity6,49
Decreased body weight, infertility, premature
death 16
Alterations
in
liver
regeneration,
hyperglycemic
conditions
due
to
gluconeogenesis, altered sleep pattern, glucose
intolerance8,50,51,52
Cancer development, improper cell division,
abnormal apoptosis16
Dyslipidemia53

CK1e/d

Familial advanced sleep phase syndrome43,54

BMAL1
CRY I and II

PER 1 and 2

1.7.2 Identification of the synthetic clock modulators

The circadian rhythm is highly pliable and can reset by external cues such as environmental
change or metabolism; therefore, small molecules can be used to modulate the rhythm13,44-48. The
purpose of drug discovery is to target either the input pathway or the feedback loop. Moreover, the
primary goal is to target the core clock component instead of components far away from the central
oscillator to avoid pleiotropic effects13. Incidentally, modern research has determined that all core
proteins are druggable, and most of them have an endogenous ligand that drives their actions. For
instance, REV-ERBa/ b employs a Heme cofactor, while RORa has been found to be regulated
by cholesterol. Alternatively, important dinucleotides such as flavin adenine dinucleotide (FAD)
and nicotinamide adenine dinucleotide (NAD) have been found to be signaling molecules for core
circadian proteins like cryptochrome (in plants and insects) and BMAL148 respectively. In plants
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and insects, FAD governs the signaling mechanism of the CRY in a light-dependent manner.
Despite retaining the FAD binding pocket, vertebrate CRYs are not photo regulated and do not
bind FAD, but the binding pocket can be targeted to regulate clock function (e.g. KL001)48.
Additionally, NAD regulates the activity of the CLOCK BMAL1 complex through a feedback
loop involving SIRT1. Fig 8 shows the structures of the endogenous ligand of the core clock
proteins.
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Figure 8: Endogenous ligands of the important circadian proteins. The structure of the ligands
is used as a reference to synthesize small drug-like molecules to target clock proteins
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Assuming that most of the clock components are under control of endogenous ligands, that
provides the lead to synthesize small drug-like molecules which can mimic the natural metabolite
and modulate the clock as well as treat diseases associated with the clock dysfunction. In particular
small-molecule screens have been assayed for their effect on circadian period and amplitude,
yielding identification of a host of clock-affecting small molecules targeting nearly all components
of the core and peripheral clock elements. In addition to testing small molecule libraries, efforts
are also being made to test FDA approved drugs that might target circadian proteins to reduce the
cost of identifying new bioactive molecules. For instance, Tamai et al. tested approximately1000
molecules from the FDA approved library and found approximately 5% of them had period
shortening abilities56.
Nevertheless, the burgeoning circadian modulator research has identified several new small
molecules which act on different clock proteins. Fig 9 shows some of the potent circadian clock
modulators synthesized and the part of the cycle/protein they act on. Additionally, Table 3
summarizes some of the drugs synthesized based on the structure of the endogenous ligand.
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Figure 9: Circadian clock modulators: Some of the circadian clock modulators and their protein
targets in the different stages of the negative feedback loop. Adapted from Ref:13
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Table 3: Summary of the small molecules synthesized to mimic the endogenous ligand of the core
circadian proteins and their therapeutic actions

Clock proteins

Endogenous ligand

Small molecule
modulators

Glucose tolerance in
obese mice42

N
OH

Cryptochrome
(Cry 1/2)

FAD

Physiological effects

O
O S
O

KL001 and
derivatives.48,57
Period-lengthening
effects

N
O

CN

Cl

KL04458

Br

O

N

O
OH

Restrict breast cancer
cell growth

OEt

2-ethoxypropaonic
acid derivative47
Inhibit
gluconeogenesis53

CO2tBu
O2N

REV-ERB

Heme

S

N

Cl

GSK411259
GSK 4112
derivatives

RORs

Cholesterol
H3CO
H3CO

Nobiletin60
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Improve glucose
homeostasis, reduce
anxiety54
O

OCH3
OCH3

O

OCH3
OCH3

Improve homeostasis
in diabetic mice

However, for the purpose of this dissertation, we will narrow down our focus to the core
clock component CRY. Henceforth, we will discuss cryptochrome and its function in mammalian
circadian rhythm, followed by drug intervention.
1.8 Cryptochrome as a target of drug discovery
1.8.1 Cryptochrome

Cryptochromes were first identified in Arabidopsis thaliana and were named
“cryptochrome” as their function was “cryptic” and for their widespread abundance in cryptogamic
plants61-63. They exhibit sequence homology with DNA photolyase and hence belong to the CPF
family (Cryptochrome photolyase family). The founding member of the family, photolyase is
found in most organisms, where it functions as a light-driven enzyme that repairs UV damaged
DNA64. Initially, widespread efforts failed to identify a photolyase in placental mammals, the
closest homologs were identified as the Cryptochrome family. Domain structures of CRYs
demonstrates that it retains a photolyase homology region characteristic of the CPF family. In
addition, it has a disordered cryptochrome C-terminal (CCT) or extension (CCE)
equivalently26,40,61,64,65. Despite high sequence homology, cryptochromes do not participate in
DNA repair activity. Instead, they sense blue light in plants and contribute to growth and
development, whereas in mammals they work in a light-independent manner and are the part of
the core circadian clock system64,66.
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Figure 10: Domain architecture of the mammalian cryptochrome: Mammalian cryptochrome
has a photolyase homology region along with a disordered C-terminal extension.

The animal cryptochrome was first discovered as a photolyase like protein with no DNA
repair activity in animals in 199566. The animal cryptochromes can be classified as CRY type I
(CRY1) and CRY type II (CRY2), which are differentiated based on the presence and function of
the FAD cofactor. While CRY1 proteins readily bind FAD and demonstrate blue light sensitivity
to participate in light-activated circadian behavior in Drosophila, CRY2 proteins are currently
believed to not bind FAD, but rather work in a light-independent manner in the mammalian
circadian clock66. As discussed above, CRY along with period (PER) acts as a repressor of BMAL1
and CLOCK. However, the mechanism by which it interacts with the complex is still elusive. As
noted, unlike other cryptochromes, which have been crystallized and the role of cofactor the flavin
adenine dinucleotide (FAD) in the signaling mechanisms are well known67,68, the mammalian
cryptochrome weakly binds FAD with an open cofactor pocket and is believed to function in an
FAD independent manner, where the FAD binding pocket has been co-opted to function as a
protein:protein interaction site21,28,40,72. Moreover, recent biochemical studies have shown CRY
regulates gluconeogenesis in mammals and therefore, could be a potential target for treating type
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II diabetes 51,69-71. Hence the development of a small molecule that can mimic FAD might not only
assist in understanding the signaling mechanisms of CRY but could also can set the stage for drug
development55.
1.8.2 Cryptochrome regulation of gluconeogenesis
Gluconeogenesis:
Gluconeogenesis, by definition, is “generation of glucose from non-carbohydrate
precursors.” It is a metabolic process and is stimulated by glucagon and epinephrine in the liver.
It is the process by which human body maintains optimal blood glucose level and hence glucose
homeostasis. During the daytime, or when the body is in its feeding cycle, glucose requirements
are fulfilled by food intake. The body utilizes the required amount of sugar and converts the rest
for storage in the form of fat. At night, or during fasting cycles, the pancreas secretes glucagon to
activate hepatic gluconeogenesis process and avoid hypoglycemic condition55,70.

Figure 11: Glucose homeostasis: During daytime or the feeding cycle, the body utilizes glucose
supplied by food-intake and stores excess glucose in muscles and adipose tissue. On the contrary,
at night time or the fasting cycle, glucagon gets secreted by the pancreas which activates the Gprotein coupled receptors and thereby cAMP. The cAMP ultimately phosphorylates CREB, and
that activates gluconeogenic genes to secrete glucose from non-carbohydrate sources.
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At the fasting cycle, glucagon secreted by the pancreas binds to the G-protein coupled
receptor (GPCR) or glucagon receptors in hepatocytes (liver cells), which in turn triggers
intracellular cyclic AMP (cAMP) resulting in CREB (cAMP response element binding)
phosphorylation and subsequent expression of gluconeogenic genes like pyruvate kinase (Pck1)
and glucose-6-phosphatase (G6pc). Importantly, gluconeogenic genes are expressed rhythmically
and are controlled in a circadian fashion51,69-71.
“High Glucose, No CRY”
Recent studies by Zhang et al. demonstrated that cryptochrome controls gluconeogenesis
process rhythmically. By luciferase in-vivo imaging technique they demonstrated that when CRY
is active it inhibits cyclic AMP production and hence modulates gluconeogenesis at the genomic
level 51,69-71.
To summarize, cryptochrome forms a “gate” for gluconeogenesis in humans. In the
morning time (or during the active feeding cycle), high CRY levels inhibit the gluconeogenesis
process. On the contrary, during nighttime (or fasting cycle), CRY levels are low, and
gluconeogenesis proceeds normally, hence it maintains an optimal level of glucose in a healthy
individual71.
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Figure 12: The cryptochrome acts as a gate for the gluconeogenesis process: Cryptochrome is
active during the feeding cycle and inhibits glucagon-stimulated cAMP production which further
prohibits the gluconeogenesis process. At the nighttime or at the fasting cycle, cryptochrome
becomes inactive and glucagon induces the gluconeogenesis process to take place.

1.8.3 Gluconeogenesis and Diabetes

Diabetes mellitus type 2 is a metabolic disorder characterized by hyperglycemia or high
blood sugars as cells become insulin-insensitive and fail to take up glucose which leads to
dysregulation of glucose homeostasis. Diabetes II is the seventh leading cause of death in the
United States. According to the US department of health and human services (2014),
approximately 29.1 million Americans have diabetes with 1.7 million diagnosed every year70.
Hyperglycemic conditions can cause several other diseases such as heart failure, obesity,
strokes, kidney failure, and blindness. Moreover, gluconeogenesis is a regular metabolic process
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which can lead to persistent hyperglycemic conditions in diabetic patient. Therefore, designing
drugs which can target the hepatic gluconeogenesis process can facilitate in maintenance of
optimal blood glucose levels73.
As discussed earlier, recent research affirmed that cryptochrome when rhythmically
expressed could inhibit the hepatic gluconeogenesis process. As such, cryptochrome was identified
as a suitable drug target. Specifically, if cryptochrome levels are modulated or stabilized through
a small molecule, then production of glucose by the process of gluconeogenesis can be suppressed.
1.9 Cryptochrome modulator
Cryptochrome is a core protein of the mammalian circadian rhythm that controls many
physiological processes. As discussed earlier in the chapter, gluconeogenesis is modulated when
cryptochrome is expressed. The big vision is to synthesize a small molecule which can stabilize or
delay the degradation process of the cryptochrome. A stabilized cryptochrome can delay the
gluconeogenesis for long and thereby help to alleviate hyperglycemic conditions in the diabetic
patient48,57,58.

Figure 13: Cryptochrome as a drug discovery target: A stabilized cryptochrome would restrict
gluconeogenesis process for a longer period which potentially aids in lowering the blood glucose
level and hence would help the diabetic patient in maintaining an optimal level of glucose.
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Hence, the goal of the small molecule intervention is to synthesize a scaffold which can
stabilize the cryptochrome and delay its degradation process. However, to date, its action in the
regulation of cryptochrome (CRY) is elusive. Notably, vertebrate CRYs (type 2 CRYs) are unique
in that they do not bind FAD, but rather employ the FAD binding site to interact with FBXL3, to
target the protein for degradation. Thus, it is plausible that identification of a small-molecule that
could compete at the FAD binding site would allow both interrogation of the signaling pathway of
CRYs, but also result in CRY stabilization through competition with FBXL3. Furthermore, such
molecules could unravel cryptochrome’s mode of action in the sleep-wake cycle, diabetes and
other related metabolic disorders. Remarkably, high throughput analysis of the effect of ~60,000
compounds on the circadian period in human osteosarcoma U2OS cell lines harboring Bmal-dLuc
reporter showed three carbazole-containing scaffolds with dose-dependent period lengthening
effects, consistent with what would be expected for a CRY-stabilizer. Among the three, KL001
showed pronounced period lengthening effect in a dose-dependent manner. KL001’s action in the
modulation of the clock could suggest potential therapeutic effect towards diabetes and other
metabolic diseases48.
1.9.1 KL001

N
OH

O
N
O

S

O

Figure 14: Structure of KL001 that could stabilize cryptochrome and delay its degradation
process.
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KL001 was found to be first of a kind of small-molecule that could stabilize CRY.
Incidentally, KL001 indeed competitively bound to the SCFFBXL3 binding site (an F-box protein
which tags cryptochrome for proteasomal degradation), hence prevents its ubiquitination process
and stabilizes cryptochrome. Cryptochrome stabilization by KL001 ultimately lengthens the
overall period of the cryptochrome, enabling the therapeutic potential40,41,57.

Figure 15: KL001 mode of action. KL001 competitively binds at the FBXL3 binding site of the
flavin and prevents it from degradation, which in turn lengthens the period.

Previous studies have shown that CRY2-FBXL3 complex involves insertion of the Cterminal tail of FBXL3 into the FAD binding pocket of the cryptochrome21,40,41, hence
competitively binding of KL001 in the FBXL3 pocket was postulated as the mechanism of KL001
induced stabilization of CRY. The postulation was further confirmed by the crystal structure of
CRY2 PHR bound by KL001. Nangle et al. compared the crystal structure with that of FBXL3
bound CRY and confirmed that KL001 and FBXL3 compete for the same FAD binding pocket.
Moreover, high resolution (1.94 Å) structures have unraveled the binding ability of the KL001 in
the FAD-binding pocket, giving better insights for drug discovery41.
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1.10 Research Objective
This dissertation mainly focuses on designing the small molecules to target the core
circadian protein cryptochrome. In this work, we have deeply investigated the crystal structure of
the cryptochrome in complex with KL001 using modeling software such as Coot and Pymol.
Insights gained from the structure-activity relationship, we have designed the “Zoltowski Library”
consisting of 10 different small molecules. In the initial part of the research, we modified the
scaffold and replaced the carbazole with Delta-carbolines, Pinoline, and Quinoxaline derivative to
target the core scaffold for improved binding to the CRY FAD binding site.
Motivated by our previous results, we further investigated the crystal structure of KL001
bound cryptochrome and designed numerous side chains for better recognition and binding.
Furthermore, we also focused on changing the linker region. All resulting compounds were tested
for activity by interrogating their effect on circadian period in U2OS cells harboring the BMAL1dLuc reporter. Although the research is in the primary stages of the circadian modulators
development, we can still get better insights to proceed with the synthesis of more compounds.
In the latter part of this dissertation, we will steer the focus to study about LOV domain
proteins of plant circadian clock. Specifically, we will focus on the study of the thermal kinetics
of LKP2 protein of Arabidopsis thaliana. We also have extended our research to examine the
thermal kinetics of LKP2 protein in an agriculturally important crop Brassica rapa.
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CHAPTER 2
SYNTHESIS OF CRYPTOCHROME MODULATOR

2.1 Introduction
Cryptochrome (CRY) is an integral part of the mammalian clock system participating in
the autoregulatory core transcription-translation feedback loop1-3. Recent studies have shown that
CRY regulates the gluconeogenesis process and hence maintains glucose homeostasis4-6.
Cryptochrome is a circadian protein that is expressed rhythmically for its function. The
anticipation was to synthesize a synthetic ligand which stabilizes CRY and prevents it from
degradation and thereby modulates gluconeogenesis. Modulation of gluconeogenesis will help a
diabetic patient with a sudden spike in the blood glucose level overnight.
Recently, a cell-based study showed a carbazole scaffold (KL001) was able to stabilize
CRY proteins resulting in period lengthening effects. KL001’s action in stabilizing CRY suggested
potential therapeutic effect towards diabetes and other metabolic diseases7 . Notably, the carbazole
moiety was found to be essential for that period-changing activity, as it was reported that replacing
it with a phenyl indole or a non-planar moiety resulted in complete loss
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of activity. Furthermore, its crystal structure indicated that KL001 is bound to the FAD binding
pocket in the precise location of the isoalloxazine ring, supporting the requirement of a planar
heterocycle at the core of CRY stabilizing drugs. Despite the fact that carbazole can mimic the
isoalloxazine ring of the FAD, it lacks critical H-bonding elements that can facilitate efficient
recognition and binding that could explain the loss of rhythm at higher KL001 concentrations8,9.
Structure-activity relationships revealed the FAD-binding site is enriched with polar
residues that bind to polar elements within the isoalloxazine ring of FAD. Therefore, we postulated
that incorporating heteroatoms into the carbazole scaffold could increase the propensity of
hydrogen bonding and facilitate recognition and binding of a small molecule9,11.
The primary purpose of this research is to introduce H-bonding characteristics to the
carbazole scaffold for efficient binding at the FAD-binding pocket7. In this research, to better
understand the functional differences of carbazole and other scaffolds, we sought to prepare
analogs varying in the nature of core scaffold and developed the “Zoltowski library.” In this
process, we have identified a simple two steps reaction that allows robust formation of deltacarbolines via benzyne synthesis.
2.2 Structure-activity relationship of KL001
The crystal structure of CRY with bound KL001 demonstrated that the carbazole ring of
KL001 buries itself in the inner cleft of the flavin adenine dinucleotide binding pocket in a manner
similar to the isoalloxazine ring of FAD. Notably, the isoalloxazine of FAD is subdivided into
three types of rings: xylene, pyrazine and pyrimidine rings. The pyrimidine ring of the FAD
participates in the critical hydrogen bonding with the polar residues present in the binding pocket.
A detailed examination of the crystal structure revealed, carbazole only mimics outer xylene and
central pyrazine moieties of the isoalloxazine ring and not the complete tricyclic system. Most
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importantly, carbazole lacks the moieties which can mimic the pyrimidine ring that participate in
critical hydrogen bonding9,11. (Fig 16)

Figure 16: Comparison of KL001 and FAD: (A): KL001 have carbazole as a scaffold (B): Flavin
adenine dinucleotide (FAD); the isoalloxazine ring of FAD is subdivided into xylene, pyrazine
and pyrimidine rings (C) Carbazole only mimics xylene and pyrazine rings of the isoalloxazine
ring and lacks substituents which can participate in hydrogen bonding with the neighboring polar
residues in the FAD binding pocket.

Moreover, a careful examination of the flavin binding site shows the presence of polar
residues like arginine (R 376) aspartic acid (D 405) and asparagine (N 411), which snuggle close
to the isoalloxazine ring and participate in significant interactions required for efficient binding.
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Notably, previous studies have shown that point mutations of aspartic acid (D405) and asparagine
(N411) are capable of abolishing the interactions between KL001 and CRY2 binding pocket7,9,10.
(Fig 17, PDB: 4mlp).

Figure 17: KL001 in a FAD binding pocket: The FAD binding site are enriched with polar
residues. Remarkably, a polar residue arginine 376 (R 376) is just in the vicinity of the carbazole
ring. Besides, another set of polar residues asparagine (N 411) and aspartic acid (D 405) are
essential for the KL001 binding.

All these observations inspired us into incorporating either an extra ring or a polar
substituent to the scaffold. That might better mimic the size of FAD, filling the FAD binding
pocket and potentially increasing binding efficiency. Furthermore, introducing substituents with
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hydrogen bonding capabilities might increase the binding efficiency through interactions with
essential polar residues in the binding site.
2.3 Synthesis of the Zoltowski Library (ZL series)
Based on insights gained from the structure-activity relationship of KL001, compounds
ZL001 to ZL005 were synthesized using different scaffolds while keeping the side chain the same
as KL001. Our overall design principle of the scaffolds was to either attach a polar side chain or
an extra ring so that the complete isoalloxazine ring can be mimicked.
We first synthesized KL001 side chain in bulk to both synthesize KL001 in the lab as a
reference molecule for biological evaluation and for further attachment of the ZL scaffolds.
2.3.1 Synthesis of KL001

We synthesized KL001 based on the published synthesis.6 The side chain was synthesized
by mesylating the furfural amine 1 using mesitylene chloride and pyridine, where pyridine acted
both as solvent and a base. The mesylated product 2 was then N-alkylated with epibromohydrin in
the presence of sodium hydride to get compound 3. The coupling reaction of the side chain with
the secondary amine of carbazole in the presence of sodium hydride yielded KL001 4 (yield 60%).
The same procedure of side chain synthesis is used for most of the ZL library7.

43

O

O

O

O
NH S
O

MsCl
Pyridine

NH 2
1

NaH / DMF
Br

O

O
S
O

O

2

N
H

N

3

N

OH

NaH / DMF
50oC

O

N
4

O

S
O

Scheme 1: Synthesis of KL001 (20%)

2.4. Design principle for ZL001
For the first compound in the library, we did not want to change the scaffold drastically,
but wanted to introduce an H-bonding moiety. To achieve this, we focused on the carboline
scaffold. Carbolines are the N-heterocyclic compounds found in many biologically active natural
and synthetic compounds. Most importantly, β-carbolines are widely distributed in nature and have
shown DNA intercalation properties to inhibit CDK (cyclin-dependent kinase), topoisomerase and
monoamine oxidase. Moreover, it interacts with 5-hydroxyserotonin receptors12.
Essentially, carbolines are pyrido-indoles, and based on the position of nitrogen with
respect to the indole ring they are named as alpha (α), beta (β), gamma (γ) and delta (δ) carbolines.
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Amongst all carbolines, δ-carboline is extremely rare in nature. Interestingly, benzo fused
δ-Carboline like cryptolepine and quindoline are found to be pharmaceutically active compounds
and have shown antimalarial, antiplasmodial and antibacterial activity. Cryptolepine is an
indoloquinoline natural product extracted from the roost of Cryptolepis triangularis used as a
traditional antimalarial drug in Central and West Africa for ages13-15.
We envisioned, δ-carboline being similar to carbazoles will bind in a similar fashion to
KL001, with the introduction of an H-bonding atom due to a nitrogen at the para position. An extra
nitrogen can potentially increase the scaffold’s propensity to participate in critical hydrogen
bonding with the polar residues in the vicinity such as arginine (R 376) (fig 18). Furthermore, it
can also interact with other polar “essential” residue asparagine N 411.
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Figure 18: ZL001 at the binding site: In ZL001, an extra nitrogen present at the para position
possibly can enhance the binding efficiency of the compound at the flavin binding site.
Presumably, it can participate in H-bonding interactions with R 376, N 411. (The fig was made
using PDB = 4MLP of KL001 complexed with CRY, the nitrogen was introduced to promote
understanding)

Delta carboline was primarily synthesized following a known synthesis using aniline as a
starting material. At first, the amino functionality of aniline was protected with pivolyl chloride in
the presence of triethylamine as a base yielding pivaloyl amino benzene 5. Amidation served two
purposes, it not only acted as a protecting group but also provided neighboring group assistance
during borination at the next step. Subsequent metalation of the compound 5 using nBuLi in
anhydrous THF followed by the treatment with trimethylborate and subsequent hydrolysis
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afforded the corresponding boronic acid derivative 5. The product 6 was coupled with 3-fluoro-2iodobenzene 7 using Suzuki coupling conditions for 48 hours. The coupled product 8 was
deprotected in 20% of sulfuric acid solution under refluxing conditions to afford the coupled
product 9. Cyclization of the resulted compound using pyridine-hydrochloride at 215 oC followed
by the treatment with ammonium hydroxide afforded δ-carboline 10 in moderate yield16,17.
3-Fluoro-2-iodopyridine used to couple with the compound 6 was also synthesized based
on a patented synthesis. Iodination of 3-fluoro-2-chloropyridine was achieved using sodium iodide
in the presence of trimethylsilane under refluxing conditions18.
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Scheme 2: Synthesis of Delta-carboline (45%)
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The above synthesis of delta-carboline involved several steps under stringent conditions
demanding longer reaction times with a moderate yield requiring purification in each step. Delta
carbazoles are essential bioactive molecules. So far, the development of an efficient cyclization
step was the focus of attention, and not much had been done to modify the coupling reaction.
Consequently, an efficient approach was needed to synthesize δ-carboline efficiently.
2.4.1 Synthesis of δ-Carbazole using Benzyne Chemistry
We were intrigued to explore the use of aryne chemistry in the preparation of carbazoles
due to its feasibility in incorporating heterocyclic rings in various natural product syntheses. Aryne
chemistry has proved useful and efficient in the synthesis of complex bioactive heterocyclic
molecules. Most importantly, aryne chemistry provides a strategic advantage in functionalizing an
aromatic ring system, because of its feasibility to form multiple carbon-carbon or a carbonheteroatom bond in a single step in a regioselective manner19.
To synthesize delta carboline through aryne chemistry, we did a retrosynthetic analysis and
found two plausible approaches: the benzyne approach or the pyridyne approach. We possibly can
synthesize either benzyne or 2,3-pyridyne precursors which could be coupled with halo-substituted
aminopyridine or phenylamine respectively to yield the desired product.

Figure 19: Retrosynthetic analysis shows two possible ways delta carbazole could be
synthesized using aryne chemistry
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2.4.1a. A 2,3-pyridyne approach for delta carboline synthesis

Pyridyne approach was captivating as the precursor can be coupled with the substituted
phenylamine, giving an opportunity to synthesize a library of substituted delta carboline with just
one precursor.

Figure 20: 2,3-Pyridyne approach for the synthesis of delta carbolines: (A) pyridyne precursor
can be coupled with the halo benzyne, the coupled product can be cyclized to yield delta carbolines.
(B): Regioselectivity of pyridyne precursor at the 2nd position.

Regrettably, 2,3-pyridynes are highly regioselective; therefore, nucleophilic substitution
exclusively takes place at the 2nd position. Incidentally, nucleophilic substitution at the 3rd position
builds up negative charge on the 2nd position that creates repulsion due to the lone pair of electrons
on nitrogen20,21. Delightfully, the approach gave the alpha carboline precursor instead, which will
be discussed in the later part of this research (ZL002).
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2.4.1b. A benzyne approach for delta carboline synthesis

It occurred to us that the reaction of o-benzyne with 2-amino-3-halo-pyridine derivative
should give a (2-halo-pyridin-3yl)-phenyl-amine intermediate that upon intramolecular cyclization
would give δ-carboline directly. Most importantly, substituted δ-carbazole could also be
synthesized by using same benzyne precursor with substituted pyridines. On the contrary, a
different substituent benzyne precursor can also be generated.

Figure 21: Benzyne approach: An in-situ generated benzyne will be coupled with the the orthoaminopyridine derivation, subsequent cyliczation yield delta carboline

Similar to pyridynes, benzyne reaction also pose some restrictions due to the
regioselectivity effect of different substituents present in the benzyne ring system. Incidentally,
substituents present in the benzyne dictate the fate of the product; for instance, benzyne precursor
with the electron donating substituent directs nucleophilic substitution regioselectivity at the meta
position. Whereas, an electron withdrawing substituents facilitate it at the ortho position. On the
contrary, a methyl substituent would yield a mixture of products. This restricted us to synthesize a
library of benzyne precursors in the lab20,21.

50

Several methods for generating o-benzyne were explored that would react with an aminopyridine derivative to give a coupled product. Many of the benzyne generation procedures required
harsh conditions, use of strong bases such as butyllithium (nBuLi) or high temperature.
Kobayashi’s method of benzyne generation is a milder approach known to generate benzyne insitu, and remarkably, the method had been used to generate several natural products. Orthotrimethylsilylphenyl triflate is a milder approach to generate benzyne which requires a fluoride
source which acts as a desilylating agent, which subsequently eliminates the bulky triflate group
leading to the formation of benzyne in-situ. Any simple fluoride source like cesium fluoride, tetran-butylammonium fluoride can be used at room temperature under an argon atmosphere with
acetonitrile as a solvent22.

Figure 22: A mild benzyne precursor: o-Trimethylsilylphenyl triflate: A fluoride source can
abstract the trimethylsilyl group, which subsequently eliminates the triflate group leading benzyne
generation
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The benzyne precursor (o-trimethylsilylphenyl triflate, 13) was synthesized using recently
reported synthesis without further optimization. The procedure was highly efficient requiring only
one purification step with approximately 66% of overall yield.
Phenol was treated with triisopropyl isocyanate in the presence of catalytic amount of
triethylamine (Et3N) to yield the corresponding carbamate 11. Ortho-metalation of the carbamate
11 using nBuLi in anhydrous diethyl ether followed by its silylation and acidic work up afforded
trimethylsilyl compound 12. Silyl triflate (benzyne precursor 13) was then conveniently formed in
a one pot carbamate cleavage/ triflation of 12. The carbamate cleavage was achieved by heating a
solution of 12 in anhydrous acetonitrile with 1-8-diazabicyclo [5.4.0] undec-7-ene (DBU) and
diethyl amine. Thereafter, N-phenyl-bis-(trifluoromethanesulfonimide) (PhNTf2) was used as a
triflate source. The compound was then purified using flash chromatography23.
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Scheme 3: Synthesis of benzyne precursor (66%)

The coupled product 14 was obtained by allowing benzyne precursor to react with a halo
substituted amino pyridine in anhydrous acetonitrile under argon atmosphere at room temperature.
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Cesium fluoride was used as a fluoride source to abstract the silyl group to generate benzyne in
situ24. The coupled product obtained was conveniently microwaved for 10 min at 180 oC with a
palladium catalyst and sodium acetate in N, N-dimethyl acetamide to obtain the δ-carboline 10 in
approximately 70% yield25.
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Scheme 4: Synthesis of Delta-Carboline from benzyne precursor (70%)

The delta-carboline 10 was coupled with the side chain 3 in presence of sodium hydride and DMF
to achieve ZL001.
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Scheme 5: Synthesis of ZL001 (57%)

Motivated with our success with the aryne chemistry, we used pyridyne precursor to
synthesize the second compound in the library, while the coupled product of the delta carboline
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was used for the third compound in the library. ZL002 and ZL003 were designed to gauge if
planarity of a scaffold is required for the efficient binding in the FAD binding pocket.
2.5 Design Principle of ZL002 and ZL003
The design principle for the next two compounds involves the use of alpha carboline and
delta carboline precursors in place of carbazole.
N
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ZL002

ZL003

We anticipated that breaking the central pyrrole ring would allow free rotations of the rings that
could potentially improve binding capacity by enhancing interactions with other residues.
Furthermore, it would allow us to understand if planarity is one of the criteria essential for the
activity of small molecules.

2.5.1. Synthesis of ZL002

As mentioned earlier in the chapter, 2,3-pyridynes are highly regioselective, and all the
nucleophilic reactions are directed towards the 2nd position (ortho-position). By taking advantage
of this behavior, we synthesized the coupled product and then linked it with the KL001 side chain.
We later planned to cyclize the coupled product to generate an alpha carboline, which could
potentially be used as another scaffold for the library. Regretfully, all our efforts to cyclize the
coupled product were futile.
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Just like benzyne precursor, a mild pyridyne precursor was synthesized based on the
published synthesis with minor modifications.
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Scheme 6: Synthesis of ZL002 (25%)

The pyridyne precursor 17 was synthesized by silylating the 2-hydroxy pyridine using
lithium diisopropyl amide as a base to yield silylated derivative 16. The compound 16 was then
treated with triflic anhydride in the presence of 2,4-lutidine in DCM to achieve pyridyne precursor
1726. Pyridyne was then generated in situ using cesium fluoride as a fluoride source in anhydrous
acetonitrile, and then allowed to react with aniline to yield the coupled product 18, which was then
attached with the side chain to achieve ZL002 19.

2.5.2. Synthesis of ZL003
For the synthesis of the third compound in the library we used delta carboline precursor as
a scaffold. Here, along with the effect of ring movement, we anticipated observing the effect of
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halogen in the binding site. We expected the chloro group might help in facilitating binding by van
der waals interactions in the flavin binding pocket.
The benzyne precursor 13 was coupled with 2-chloro-3-amino pyridine in presence of
cesium fluoride. Side chain 3 was attached to the coupled product 14 by generating a nitrogen
anion in presence of sodium hydride, then reaction undergoes ring opening step when heated with
side chain 3 at 50 oC.
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Scheme 7: Synthesis of ZL003 (25%)

So far, subtle changes were made in the carbazole ring system for the synthesis of a novel
KL001 analog. It intrigued us to observe the effect if the carbazole is replaced by another known
tricyclic ring system. Particularly, if the tricyclic system could mimic the structure of natural
endogenous metabolite which are known to work in the circadian fashion. The design principle of
the fourth compound in the library relies on using a scaffold similar in the structure of the
neurotransmitters like serotonin and melatonin. Pinoline is tetrahydro-β-carboline as a scaffold
and is structurally similar to both serotonin and melatonin and is a natural biological metabolite of
melatonin. Thus, if it demonstrated physiological effects on circadian period, it could be an
endogenous ligand of CRY that modulates activity30.
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Figure 23: Natural Metabolite: Structural similarity of pinoline with the natural metabolites,
serotonin and melatonin

2.6 Design Principle of ZL004

NH

O
N
H

The design principle for ZL004 involved substitution of carbazole with pinoline, which is
a natural metabolite. Pinoline is tetrahydro-β-carboline and is suggested to be produced in the
pineal gland during the production of melatonin and is believed to follow the circadian rhythm2730

. Hence, the anticipation was the scaffold would potentially assist in maintaining the circadian

rhythm. Besides this, we anticipated that the methoxy group present in the structure could
potentially participate in much stronger hydrogen bonding with the polar residues in the vicinity.
Furthermore, the NH group present in the cyclohexane ring could also enhance the binding
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capability of the molecule. Pinoline was synthesized by the cyclization of 5-methoxy tryptamine
by reported synthesis30,31.

Figure 24: Structure-activity of ZL004. Pinoline as a scaffold will place two substituents with
the capability of participating in hydrogen bonding interactions on both sides of the tricyclic ring
system. The methoxy group, presumably fill the portion of the pyrimidine ring of the isoalloxazine
ring system. While on the other side, the hydrogen of secondary nitrogen can participate in critical
interactions with the neighboring residues.The figure was generated using PDB = 4MLP for
understanding purposes.
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Scheme 8: Synthesis of ZL004 (55%)

5-Methoxy tryptamine was heated with paraformaldehyde in 10:1 mixture of acetic acid
and methanol to get pinoline 21. The primary amine of the pinoline was then selectively protected
with Boc anhydride in THF, the protected scaffold 22 was attached to the side chain 3 of KL001
using sodium hydride in DMF. The Boc-protected amine 23 was then deprotected using
trifluoroacetic acid in DCM to get ZL004 2430,31.
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2.7 Design Principle of ZL005
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6H-Indolo[2,3-b]quinoxaline

For the fifth compound in the library, benz-quinoxaline derivative was chosen for
substituting carbazole. The quinoxaline derivative was anticipated to mimic the FAD efficiently
than carbazole in KL001. We envisioned, presence of one extra ring could potentially enhance pipi stacking and non-covalent interactions between the quinoxaline rings with histidine H 373
present in the vicinity. Additionally, it can participate in salt bridge formation with asp (D 405)
and arginine (R 376). Furthermore, just like isoalloxazine ring system, quinoxaline has a pyrazine
like moiety that could potentially participate in hydrogen bonding with adjacent arginine R 376.
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Figure 25: Structure-acitivity of ZL005: Benzquinoxaline will physically add one more ring in
the tricyclic ring system, which might potentially eliminate the requirement of having a
susbstituent in a tricyclic ring system.

The scaffold was conveniently prepared by the condensation reaction of isatin and ophenylenediamine. A solution of isatin and ortho-phenylenediamine in acetic acid was
microwaved for 10 min at 150 oC to get the desired compound 25 32-33. The scaffold such obtained
was then coupled with the side chain in the presence of sodium hydride in DMF at 60 oC to obtain
ZL005 26.
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Scheme 9: Synthesis of ZL005

2.8 Materials and methods
All the reactions were performed in dried glassware under an argon atmosphere. All
reagents were purchased from Sigma Aldrich (St. Louis, MO), Fisher scientific (Waltham, MA),
Alfa Aesar (Ward Hill, MA), Chem Impex (Wood Dale, IL) and used as it was received. The
deuterated solvents (CDCl3, DMSO-d6) were purchased from Cambridge Isotope Laboratories
(Cambridge, MA). 1H-NMR and

13

C NMR spectra were recorded using 500 MHz Jeol

multinuclear NMR spectrometer in the department of chemistry at Southern Methodist University.
All chemical shifts are reported in the standard notation of parts per million using the peak of
residual proton signals of the deuterated solvent as an internal reference. The coupling constant
units are in Hertz (Hz) splitting patterns are indicated as follows: br, broad; s, singlet; d, doublet;
t, triplet; q, quartet; m, multiplet; dd, doublet of doublets; dt, doublet of triplets. Microwave
reactions were carried out in CEM DiscoverTM. Column chromatography was carried out on
Combi-Flash instrument by using pre-packed silica gel columns.
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2
N-(Furan-2-ylmethyl)-methane sulfonamide (2)
Furfuryl amine (20 g, 20.5 mmol, 1 eq.) was dissolved in 150 mL of pyridine under an
argon atmosphere at room temperature. The reaction mixture was cooled to 0 oC before
methanesulfonyl chloride (24 mL, 30.8 mmol, 1.5 eq.) was introduced dropwise. The reaction was
then allowed to stir at the room temperature overnight. The reaction mixture was quenched with
water, the aqueous layer was extracted with DCM thrice. The combined organic layer was washed
successively with 5% hydrochloric acid followed by water, brine, dried over sodium sulfate,
concentrated under vacuum to yield dark brown liquid (32 g, 99%). The compound was confirmed
by 1H-NMR and used for the next step without further purification. 1H NMR (500 MHz, CDCl3)
δ7.31 (s, 1H), δ6.32 (d, J =1.75 Hz, 1H), δ5.03 (br, 1H), δ 4.31(d, J = 5.7 Hz, 2H), δ2.82 (s, 3H).

3
N-(Furan-2-ylmethyl)-N-(oxiran-2-ylmethyl)-methane sulfonamide (3)
N-(Furan-2-ylmethyl)-methane sulfonamide (20 g, 114 mmol, 1 eq.) was dissolved in N,
N- formamide (150 mL) at the room temperature under an argon atmosphere. The reaction mixture
was cooled down to 0 oC -5 oC followed by addition of sodium hydride (60% dispersion in mineral
oil, 6.80 g, 171 mmol, 1.5 eq.) in portions over the period of 15 min, while it was still stirring over
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an ice bath. The reaction mixture was allowed to warm up to the room temperature for 30 - 45 min.
It was again cooled down to 0 oC - 5 oC and added epibromohydrin (12 mL, 171 mmol, 1 eq.)
dropwise. The reaction flask was then equipped with condenser and the reaction was heated at 50
o

C overnight under an argon atmosphere. The reaction was quenched by adding water and

extracted with ethyl acetate thrice. Combined organic layer was washed with brine, dried over
sodium sulfate. Concentration under vacuum afforded 45 g (quant.) brown liquid.

N
HO
O
O
S
N

O

4
N-(3-(9H-carbazol-9-yl)-2-hydroxypropyl)-N-(furan-2-ylmethyl)-methanesulfonamide
KL001: (4)
The carbazole (20 g, 86 mmol, 1 eq.) was dissolved in anhydrous 150 mL of N, Ndimethylformamide under an argon atmosphere at the room temperature. The reaction mixture was
further cooled down to 0 oC -5oC for 15 min. To the cooled reaction mixture, added sodium hydride
(60% dispersion in mineral oil, 5.80 g, 129 mmol, 1.5 eq.) over the period of 15 min. After
complete addition, the reaction mixture was allowed to stir at room temperature for 30min before
cooling it down again to 0 -5

o

C N-(furan-2-ylmethyl)-N-(oxiran-2-ylmethyl)-methane

sulfonamide dropwise was then introduced dropwise while the reaction mixture was stirring over
an ice bath. After complete addition, the reaction flask was equipped with a condenser and heated
at 50 oC overnight under argon atmosphere. The work up was done by quenching the reaction with
water and extracting it with ethyl acetate thrice. The combined organic layer was washed with
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water followed by the brine solution, dried over sodium sulfate and concentrated under vacuum.
The crude obtained was then purified by flash chromatography and sticky solid was obtained. The
sticky solid was crystalized by dissolving in dichloromethane and then adding n-hexane drop wise
till white crystalline solid settled down in the round bottom flask. The solid was then filtered,
washed with hexane and dried under vacuum. 7.0 gm of white solid obtained was confirmed by
1

H and 13C-NMR. 1H-NMR (DMSO-d6) δ 8.11 (d, J =7.45 Hz, 1H) δ 7.52 (d, J =8.6 Hz, 3H), δ

7.43 (t, J = 1.15 Hz, 2H) δ 7.19 (t, J = 8 Hz, 2H) δ 6.28 (t, J = 1.7, 1 H) δ 5.38 (1 H, br, OH, s) δ
4.48 (m, 2H) δ 4.43 (m, 1H), δ 4.19 (m, 1H) δ 4.10 (s, br., 1H) δ 3.35 (m, 1H) δ 3.20 (m, 1H) δ
2.88 (s, 3H); 13C NMR (DMSO-d6, 500 MHz) δ 150, 143.75, 140.97, 126.12, 122.65, 120.6, 119.2,
110.5, 110.0, 68.5, 60.4, 47.4, 45.0, 39.9, 38.2.

NH
O

5
N-phenylpivalamide (5)
The aniline (5 g, 53.7 mmol, 1eq.) was dissolved in 50 mL dichloromethane at the room
temperature under an argon atmosphere. The reaction mixture was then cooled down to 0 oC-5 oC
for 10 min. To the cooled reaction mixture added triethylamine (30 mL, 215 mmol, 4 eq.) followed
by the addition of pivaloyl chloride (9.9 mL, 805 mmol, 15 eq.) drop wise. The reaction was then
continued to stir at 0 oC-5 oC for 15-20 min, then allowed to stir at the room temperature overnight.
The workup was done by concentrating the reaction mixture under vacuum followed by addition
of 200ml of water. The aqueous layer was then extracted with dichloromethane thrice. The
combined organic layer was washed with 5% hydrochloric acid followed by the saturated solution
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of sodium bicarbonate and the brine solution. It was then concentrated under vacuum to yield
reddish brown solid which was purified by the flash chromatography to get 9.1 g of white solid.
1

H NMR (CDCl3, 500 MHz) δ 7.52 (d, J = 7.4 Hz, 2H) δ 7.30 (t, J = 2.3 Hz, 2H) δ 7.2 (t, J = 1.15

Hz, 1H) δ 1.31 (s, 9H).

O
NH
OH
B
OH

6
2-(pivaloylamino)-benzeneboronic acid (6)
N-phenylpivalamide (5 g, 25 mmol, 1 eq.) was dissolved in 50 mL of anhydrous THF under
an argon atmosphere at the room temperature. The reaction mixture was then allowed to stir over
an ice bath followed by dropwise addition of butyl lithium (15 mL, 75 mmol, 3 eq.). After complete
addition, the reaction mixture was allowed to warm up to the room temperature gradually. The
reaction mixture was continued to stir at room temperature for 5 hours. After 5 hours,
trimethylborate was introduced to the reaction mixture drop wise at 0 - 5 oC. After complete
addition, the reaction mixture was continued to stir at 10 oC for 2 hours. The reaction mixture was
then quenched by adding 5% hydrochloric acid till its pH became acidic. The aqueous layer was
then extracted with dichloromethane thrice. The combined organic layer was then washed with
water, dried over sodium sulfate and concentrated under vacuum. The coffee brown fluffy solid
obtained was dissolved into the minimum quantity of acetone followed by the addition of water
dropwise which had crystallized the white solid. The solid such obtained was washed with water
and filtered. 0.7 gm of pure white solid was obtained, verified by 1H NMR. 1H NMR (DMSO-d6
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500 MHz) δ 11.14 (s, br, OH), δ 7.67 (d, J = 8.25, 1 H) δ 7.57 (d, J = 7.45, 2 H) δ 7.20 (t, J = 6.9
Ar H).
Alternative synthesis of borate derivative using 2-Bromo-benzylpivaloyl amide (97 mmol)
was dissolved in 250 mL of anhydrous tetrahydrofuran under argon atmosphere. n-butyl lithium
(234 mmol) was added drop wise after cooling reaction mixture to -65 to -70 oC (temperature was
maintained using acetone dry ice mixture). Reaction was continued to stir at -65 to -70 oC for 1
hour. After 1-hour, triisopropyl borate (250 mmol) was introduced to the reaction mixture drop
wise over the period of 30 minutes, while it was still stirring at -65 to -70 oC. The reaction mixture
was then continued to stir at -70 oC for 4 hours. After 4 hours reaction was quenched by adding
hexane and allowed to warm up to 0-5 oC. Continued stirring for 2 hours lead to generation of
solid. The solid such obtained was filtered and washed with saturated solution of ammonium
chloride. The aqueous layer was then extracted with DCM. Combined organic layer was dried over
sodium sulfate and concentrated. The coffee brown fluffy sold obtained was dissolved in a
minimum volume of acetone followed by water, which crystallized the white solid. The solid such
obtained was washed filtered and washed with water. 4 gm. of pure white solid was obtained,
verified by 1H NMR. 1H NMR (DMSO-d6 500 MHz) δ 11.14 (s, br, OH), δ 7.67 (d, J = 8.25 Hz,
1H) δ 7.57 (d, J = 7.45 Hz, 2H) δ 7.20 (t, J = 6.9 Hz).
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7
2-Iodo-3-fluoropyridine (7)
3-Fluoro-pyridine (5 g, 38.01 mmol, 1 eq.) was dissolved in 75 mL of 1, 4-dioxane at the
room temperature under an argon atmosphere. To the solution added chlorotrimethylsilane (9.5
mL 76.0 mmol, 2 eq.) followed by the addition of sodium iodide (27.5 gm, 190 mmol, 5 eq.). After
addition, the reaction mixture was allowed to reflux at 80 oC overnight under an argon atmosphere.
The work up was done by quenching the reaction mixture with water and extracting the aqueous
layer with ethyl acetate. The combined organic layer was washed with water followed by the brine
solution, dried over sodium sulfate and concentrated under vacuum. From this approximately 7
gm of crude compound was obtained. Confirmed by 1H NMR. It was used for further reaction
without any further purification. 1HNMR (CDCl3, 500 MHz) δ (ppm) δ 8.21 (m, 1H) δ 7.30 (m,
1H) δ 7.24 (m, 1H).
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8
2’-Fluoro[1,1’-biphenyl]-2-pivaloylamine (8)
2-(pivaloylamino-benzeneboronic acid (0.442 g, 20 mmol, 1 eq.) was added to the mixture
of 2 M potassium carbonate and ethanol at the room temperature. To this mixture 2-Iodo-3fluoropyridine (0.445 g, 20 mmol, 1 eq.) dissolved in deoxygenated toluene was introduced. The
resulting mixture was allowed to stir at room temperature under argon atmosphere for about 1
hour. Tetrakis-triphenyl phosphorus palladium (0.07 g, 30 mmol, 1.5 eq.) was added to the reaction
mixture after one hour of stirring at room temperature. The reaction mixture was then allowed to
reflux at 100 oC for 48 hours. The work up was done by filtering out the solid formed in the reaction
mixture and drying the organic layer over sodium sulfate followed by concentrating down the
organic layer under vacuum. The crude such obtained was then purified by flash chromatography
and then was characterized by 1H NMR. 1H NMR (CDCl3, 500 MHz) δ (ppm) δ 8.44 (dd, J = 16
Hz, J = 9.2 Hz, 2 H) δ 7.66 (m, 1 H) δ 7.58 (m,1 H) δ 7.41 (t, J = 6.85 Hz, 1H) δ 7.33 (m 1 H) δ
7.15 (t, J = 1.15 Hz, 1H) δ 1.23 (s, 9H).
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9
2’-Fluoro[1,1’-biphenyl]-2-amine (9)
2’-Fluoro[1,1’-biphenyl]-2-pivaloylamine was refluxed (100 oC) with 20% sulfuric acid
overnight or until the reaction goes to completion. Adding 2 N sodium hydroxide till the pH
became basic quenched the reaction. The aqueous layer was then extracted with dichloromethane.
The combined organic layer was washed with the brine solution, dried over sodium sulfate,
concentrated under the vacuum. The compound was used for the next step without any further
purification. 1H NMR (CDCl3, 500 MHz) δ (ppm) δ 8.44 (m, 2 H), δ 7.48 (m, 2 H), δ 7.22 (m,
3H), δ 6.8 (m, 2H).
N

N
H

10
Delta-Carboline (10)
2’-Fluoro[1,1’-biphenyl]-2-amine (1.5 g, 79.6 mmol, 1 eq.) and pyridinium hydrochloride
(74 g, 640 mmol, 8 eq.) was refluxed at 210-215 oC for 20-30 minutes. The hot reaction mixture
was then poured in ice cold ammonia solution and stirred vigorously. The aqueous layer was then
extracted with ethyl acetate. Combined organic layer was then dried over sodium sulfate and
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concentrated under vacuum. The crude such obtained was purified with flash chromatography. 160
mg of pure compound was obtained, which was further characterized by 1H NMR. MP = 210 oC –
216 oC. 1H NMR (500 MHz, DMSO-d6) δ 11.39 (s, 1H, NH), δ 8.4 (dd, 1H, J = 1.15 Hz, J = 3.45
Hz, Py-H), δ 8.16 (d, 1H, J = 7.45 Hz, Py-H), δ 7.8 (dd, 1H, J = 1.15 Hz, J = 6.85 Hz, Py-H), δ
7.53 (d, 1H, J = 8.6 Hz, Ar-H), δ 7.45 (td, 1H), δ 7.35 (dd, 1H J = 4.6 Hz, J = 4.5 Hz, Ar-H), δ
7.21 (t, 1H, J = 7.5, Ar-H).
N
N
HO
O
O
S
N

O

15
N-(furan-2-ylmethyl)-N-(2-hydroxy-3-(5H-pyrido[3,2-b]-indol-5-yl)-propyl)-methane
sulfonamide: (ZL001) (15)

δ-Carbazole (0.160 g, 0.95 mmol, 1 eq.) was dissolved in anhydrous 150 mL of N, Ndimethylformamide under argon atmosphere at room temperature. The reaction mixture was
further cooled down to 0-5 oC for 15 min. To the cooled reaction mixture, added sodium hydride
(60% dispersion in mineral oil, 1.4 mmol, 1.5 eq.) in batches. After addition reaction mixture was
allowed to stir at room temperature for 30 min before cooling it down again to 0 - 5 oC. N-(Furan2-ylmethyl)-N-(oxiran-2-ylmethyl)-methane sulfonamide (0.219 g, 0.95 mmol, 1 eq.) was then
introduced to the reaction mixture drop wise while it was stirring over an ice bath. After complete
addition, the reaction flask was equipped with a condenser and heated at 50 oC overnight under an
argon atmosphere. The work up was done by quenching the reaction with water and extracting it
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with ethyl acetate. The combined organic layer was washed with water and the brine solution,
dried over sodium sulfate and concentrated under vacuum. The crude such obtained was
crystallized by dissolving it in dichloromethane and ethyl acetate mixture and then by adding
hexane drop wise. White solid such obtained was filtered and further purified by flash
chromatography. 60 mg (57%) of the pure compound was obtained which was verified by the 1H
and

13

C-NMR. 1H NMR (DMSO-d6, 500 MHz) δ (ppm) δ 8.42 (s, 1H) δ 8.16 (s, 1H) δ 7.85 (s,

1H) δ 7.46 (m, 4H) δ 7.24 (s, 1H) δ 6.91 (s, 1H) δ 5.72 (s, br, OH) δ 5.31 (s, 1H) δ 4.67 (d, J =
15.5 Hz, 1H) δ 4.52 (d, J = 15.5 Hz, 1H) δ 4.3 (m 1H) δ 4.2 (m 1H) δ 4.1 (s, br,1H) δ 2.9 (s, 3H).
13

C NMR (DMSO-d6, 500 MHz) δ (ppm) 141.64, 128.35, 127.36, 120.00, 117.39, 110.62, 68.19,

40.36, 40.20, 40.03.

O

NH
O

11
Isopropyl-carbamic acid phenyl ester (11)
Isopropyl isocyanate (2.5 mL ,39.8 mmol, 1.5 eq.) was slowly added to the mixture of
phenol (4.8 g, 26 mmol, 1 eq.) and triethylamine (1.4 mL, 5.3 mmol, 0.2 eq.) in dichloromethane
at the room temperature under an argon atmosphere. After stirring at room temperature for 120
min, it was concentrated down under vacuum. The compound was isolated as white powder, it was
then analyzed by 1H NMR and gas chromatography and used without further purification. 81%
yield. 1H NMR (500 MHz, CDCl3) δ 7.34 (t, J = 7.7 Hz, 2H, Ar-CH), δ 7.18 (t, J = 7.15 Hz, 1H,
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Ar-CH), δ 7.1 (d, J = 7.45 Hz, 2H, Ar-CH), δ 4.84 (s, 1H, N-H), δ 3.91-3.88 (m, 1H, CH), δ 1.19
(d, J = 6.3 Hz, 6H, CH3).

O

NH
O
TMS

12
Isopropyl-carbamic acid-2-trimethylsilanyl-phenyl ester (Silyl Carbamate) (12)
A solution of Isopropyl-carbamic acid phenyl ester (2.0 g, 11.2 mmol, 1 eq.) in diethyl
ether (25 mL) was charged with TMEDA (1.8 mL, 12.2 mmol, 1.1 eq.) and TBSOTf (2.8 mL, 12.2
mmol, 1.1 eq.) at 0 oC under argon atmosphere. It was gradually allowed to warm up to 25 oC and
remaining TMEDA (3.35 mL, 22 mmol, 2 eq.) was added. nBuLi (2.5 M, 11.2 mmol, 2 eq.) was
slowly introduced to the reaction mixture at -78oC over the period of 45 min. The reaction was
continued to stir at -78 oC for 60 min. After that, trimethylsilyl chloride (5.0 mL, 39 mmol, 3.5
eq.) was added over the period of 35 min and the reaction was continued to stir at -78 oC for 90
min. The reaction mixture was quenched by a saturated solution of sodium bisulfate (200 mL), and
the reaction was gradually allowed to warm up to room temperature. Work up was done by
separating the organic layer; the organic layer was further washed with sodium bisulfate solution,
dried over sodium sulfate and concentrated under vacuum. The white solid such obtained was
analyzed using 1H NMR and used without purification. Yield: 77%. 1H NMR (500 MHz, CDCl3)
δ 7.4 (d, J = 6.3 Hz, 1H, Ar-CH), δ 7.3 (m, 1H, Ar-CH), δ 7.16 (t, J = 7.4 Hz, 1H, Ar-CH), δ 7.1
(t, J = 7.4 Hz, 1H, Ar-CH), δ 4.8 (s, 1H, NH), δ 3.9 (m, 1H, CH), δ 1.2 (d, J = 5.7 Hz, 6H, CH3),
δ 0.3 (s, 9H, CH3).
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13
Trimethylsilyl-2-phenyltriflate (Benzyne Precursor) (13)
1, 8-Diazabicyclo-[5.4.0]-undec-7-ene (DBU) (3.80 mL, 26 mmol, 1.5 eq.) and
diethylamine (2.15 mL, 20 mmol, 1.2 eq.) was slowly introduced to the solution of silyl carbamate
(4.38 g, 17 mmol, 1 eq.) in acetonitrile (30 mL) at room temperature under an argon atmosphere.
The mixture was then heated at 40 oC for 45 min. It was then cooled down to room temperature; a
solution of PhNTf2 (9.3 g, 26 mmol, 1.5 eq.) in acetonitrile (25 mL) was slowly introduced drop
wise over the period of 15 min. The resulting mixture was continued to stir at the room temperature
under argon atmosphere for 120 min. The workup was done by washing the organic layer with
saturated solution of sodium bisulfate and 10% sodium hydroxide solution twice. The organic layer
was then dried over sodium sulfate, concentrated under vacuum. The resulting crude liquid was
purified by flash chromatography and verified by 1H NMR. Yield % = 65. 1H NMR (500 MHz,
CDCl3) δ 7.54 (dd, J =5.6 Hz, 1H, Ar-CH), δ 7.45-7.42 (m, 1H, Ar-CH), δ 7.35-7.32 (m, 2H, ArCH), δ 0.36 (s, 9H, CH3).
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(2-Chloro-pyridin-3-yl)-phenyl-amine (14)
3-Amino-2-Chloro pyridine (0.86 g, 6.7 mmol, 2 eq.) dissolved in acetonitrile (15 mL) was
added to oven dried cesium fluoride (1.02 g, 6.7mmol, 2 eq.) under an argon atmosphere at the
room temperature. Trimethylsilyl-2-phenyltriflate (1.0 g, 3.35 mmol, 1 eq.) dissolved in
acetonitrile (40 mL) was slowly introduced to the reaction mixture over the period of 8 hours, by
using a syringe pump. The reaction mixture was continued to stir for next 8 hours after complete
addition. The reaction was monitored by thin layer (3:7 EtOAC:Hexane) and gas chromatography.
The reaction was quenched by water; the aqueous layer was then extracted by ethyl acetate thrice.
The combined organic layer was further washed with water and brine, dried over sodium sulfate,
concentrated under vacuum. The crude solid such obtained was purified by flash chromatography
Yield = 41%. 1H NMR (500 MHz, CDCl3) δ 7.87 (d, J = 4.6 Hz, 1H, Py-H), δ 7.5 (d, J = 8 Hz,
1H, Py-H), δ 7.34 (t, J = 7.5 Hz, Py-H), δ 7.2-7.1 (m, 4H, Ar-H).
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5H-pyrido [3, 2-b] indole (δ-Carbazole) (10)
(2-Chloropyridin-3-yl)-phenylamine (0.153 g, 0.75 mmol, 1 eq.) was mixed with sodium
acetate (0.249 g, 1.83 mmol, 2.5 eq.) and Pd (PPh3)2Cl2 (0.042 g, 0.053 mmol, 8 mol%) in a 10
mL microwave vial. The vial was then flushed with argon for 5 min. N, N-Dimethyl acetamide (1
mL) was then added to the mixture, which was flush with argon for another 5 min. The vial was
then heated to 180 oC in CEM DiscoverTM microwave oven at a power level 100 W for 10 min.
The reaction mixture was then cooled down to room temperature, diluted with 60 mL of methanol
and concentrated under vacuum. The crude product was purified by flash chromatography. The
compound was isolated as a white solid in a 70% yield. MP = 210 oC – 216 oC. 1H NMR (500
MHz, DMSO-d6) δ 11.39 (s, 1H, NH), δ 8.4 (dd, 1H, J = 1.15 Hz, J = 3.45 Hz, Py-H), δ 8.16 (d,
1H, J = 7.45 Hz, Py-H), δ 7.8 (dd, 1H, J = 1.15 Hz, J = 6.85 Hz, Py-H), δ 7.53 (d, 1H, J = 8.6 Hz,
Ar-H), δ 7.45 (td, 1H), δ 7.35 (dd, 1H J = 4.6 Hz, J = 4.5 Hz, Ar-H), δ 7.21 (t, 1H, J = 7.5, Ar-H).
TMS
N
H

O

16
3-Trimethylsilanyl-1H-pyridin-2-one (16)
2-Hydroxypyridine (3.0 g, 31.5 mmol, 1 eq.) was dissolved in diethyl ether (75 mL) under
an argon atmosphere at room temperature. The reaction mixture was then allowed to stir over an
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ice bath (0 oC to 5 oC) for about 10-15 min. After that, lithium diisopropylamide (2 M, 34.5 mL
69.3 mmol, 2.2 eq.) was drop-wise introduced to the cooled reaction mixture. After complete
addition, reaction mixture was continued to stir over an ice bath for 10 min, chlorotrimethylsilane
(6.2 mL, 72.5 mmol, 2.3 eq.) was slowly added to the reaction mixture while it was still stirring
over an ice bath (0 oC -5 oC). The reaction mixture was then gradually warmed up to the room
temperature and continued to stir overnight. Workup was done by filtering out the solid generated
in the reaction, the filtrate such obtained was concentrated under vacuum. The column
chromatography of the crude afforded 1.72 g white solid. 1H NMR (500 MHz, CDCl3) δ 7.60 (d,
J = 4.55Hz, 1H) δ 7.44 (dt J = 2.3 Hz, J = 6.85 Hz, 1H) δ 6.32 (m, 1H) δ 0.27 (s, 9H).
TMS
N

OTf

17
Trifluoro-methanesulfonic acid 3-trimethylsilanyl-pyridin-2-yl ester (pyridyne precursor)
(17)
3-Trimethylsilanyl-1H-pyridin-2-one (1.72 g, 10.2 mmol, 1 eq.) was dissolved in DCM (10
mL) under argon atmosphere. 2,6-lutidine (1.4 mL, 12.3 mmol, 1.2 eq.) was then introduced to the
reaction mixture drop-wise. Furthermore, reaction mixture was allowed to cool down to 0 oC, for
5 min., triflic anhydride (2 mL, 11.3 mmol, 1.1 eq.) was then gradually introduced to the cooled
reaction mixture. Reaction mixture was then warmed up to room temperature and continued to stir
with continuous monitoring by thin layer and gas chromatography. Allowed it to stir overnight at
room temperature under argon. Reaction mixture was concentrated under vacuum and directly
purified through flash chromatography 2.94 g liquid obtained. 1H NMR (CDCl3 500 MHz) δ 8.3
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(dd J = 4.6 Hz, J = 2.25 Hz, 1H) δ 7.90 (dd, J = 4.9 Hz, J = 7.4 Hz, 1H) δ 7.30(dt, J=5.15Hz,
J=7.65, 1H) δ 0.36 (s, 9H).

N

N
H

18
N-phenylpyridin-2-amine (18)
Aniline (0.30 g, 3.2 mmol, 1 eq.) dissolved in acetonitrile (10 mL) was added to cesium
fluoride (1.5 g, 9.6 mmol, 3 eq.) under argon atmosphere at room temperature. The pyridyne
precursor (1.04 g, 3.5 mmol, 1.1 eq.) dissolved in acetonitrile (10 mL) was slowly introduced to
the reaction mixture. The reaction was continued to stir for next 8 hours after complete addition.
The reaction was monitored by thin layer (3:7 EtOAc:Hexane) and gas chromatography. The work
up was done by quenching the reaction with water; aqueous layer was then extracted by ethyl
acetate thrice. Combined organic layer was further washed with water and brine, dried over sodium
sulfate, concentrated under vacuum. The crude was purified by flash chromatography, isolated as
yellow solid. Yield = 41%. 1H NMR (500 MHz, CDCl3) δ 8.58 (d, J = 1.15 Hz, 1H), δ 8.42 (d, J
= 8 Hz, 1H, Py-H), δ 7.34 (t, J = 7.5 Hz, Py-H), δ 7.2-7.1 (m, 4H, Ar-H).
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N-(furan-2-ylmethyl)-N-(2-hydroxy-3-(phenyl(pyridin-2yl)-amino)-propyl)-methane
sulfonamide (19)
N-phenylpyridin-2-amine (0.160 g, 0.95 mmol, 1 eq.) was dissolved in anhydrous 10 mL
of N, N-dimethylformamide under an argon atmosphere at the room temperature. The reaction
mixture was further cooled down to 0-5 oC for 15 min. To the cooled reaction mixture, added
sodium hydride (1.4 mmol, 1.5 eq.) in batches over the period of 15 min. After complete addition,
the reaction mixture was allowed to stir at the room temperature for 30 min before cooling it down
again to 0 - 5 oC. To the cooled reaction mixture N-(Furan-2-ylmethyl)-N-(oxiran-2-ylmethyl)methane sulfonamide (0.219 g, 0.95 mmol, 1 eq.) dissolved 5 mL of DMF was introduced drop
wise. After addition, the reaction flask was equipped with a condenser and heated at 50 oC
overnight under an argon atmosphere. The work up was done by quenching the reaction mixture
with water and extracting it with ethyl acetate. The combined organic layer was washed with water
followed by the brine solution, dried over sodium sulfate and concentrated under vacuum. The
crude such obtained purified by the flash chromatography. 75 mg of pure compound was obtained.
The compound was characterized by 1H NMR. 1H NMR (500 MHz DMSO-d6) δ 8.07 (d, J = 1.1
Ar-H), δ 7.40-7.24 (m, 6-Ar-H), δ 7.54 (d, J = 1.2 Ar-H), δ 6.62 (d, J = 1.5 1Ar-H), δ 6.3-6.2 (m,
3Ar-H), δ 5.4 (s. br, OH), δ 4.4-4.3 (dd, J = 16, J = 36, 2 H), δ 2.7 (s, CH3).
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2,3,4,9-Tetrahydro-1H-β-carboline (Pinoline): (21)
5-methoxytryptamine (2 g, 10.5 mmol, 1 eq.) was dissolved 10:1 mixture of acetic acid (38
mL) and methanol (3.8 mL) at the room temperature under an argon atmosphere.
Paraformaldehyde (0.380 g, 12.6 mmol, 1.2 eq.) was then slowly introduced to the reaction mixture
at room temperature. The solution was then heated at 80 oC for an hour, reaction was continuously
monitoring by the gas chromatography. The mixture was then basified with ammonium hydroxide
solution. The aqueous layer was extracted with DCM thrice. The combined organic layer was
washed with water followed by the brine solution, dried over sodium sulfate and concentrated.
1.56 g of brown solid obtained which was purified by flash chromatography followed by column
chromatography. The white solid obtained was verified by the 1H NMR. 1H NMR (500 MHz,
DMSO- d6) δ 10.3 (s, br,1H) δ 7.11 (d, J = 9.2 Hz, 1H) δ 6.80 (s, 1H) δ 6.59 (dd, J = 2.3 Hz, J =
8.6 Hz, 1H) δ 4.61 (s, 2H) δ 3.84 (s, 3H), δ 2.90 (t, J = 5.7 Hz, 2H) δ 2.51 (t, J = 5.7 Hz, 2H).
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22
tert-butyl-6-methoxy-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]-indole-2-carboxylate (22)
Boc anhydride (2.3 g, 7.72 mmol) was dissolved in THF (70 mL) at the room temperature
under an argon atmosphere. The reaction mixture was then allowed to stir at 0 oC over an ice bath
for 10 min. 1.56 g of pinoline dissolved in THF (10 mL) was then slowly introduced to the cooled
reaction mixture dropwise. After that, the reaction was allowed to stir at room temperature
overnight. The reaction was quenched by a saturated solution of sodium bicarbonate (30 mL). The
aqueous layer was then extracted with diethyl ether thrice. The combined organic later was washed
with water followed by the brine solution, dried over sodium sulfate and concentrated. Flash
chromatography of the crude afforded 0.930 g white solid, which was confirmed by 1H NMR. 1H
NMR (CDCl3, 500 MHz) δ 7.20 (d, J = 8.6 Hz, 1H) δ 6.92 (s, 1H) δ 6.8 (dd, J = 2.25 Hz, J = 8.55
Hz, 1H) δ 4.61 (s, 2H) δ 3.84 (s, 3H) δ 3.75 (t, J = 8.5 Hz, 2H) δ 2.75 (t, J = 5.7, 2H) δ 1.49 (s,
9H).
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9-[3-(Furan-2-ylmethyl-methanesulfonyl-amino)-2-hydroxy-propyl]-6-methoxy-1,3,4,9tetrahydro- β-carboline-2-carboxylic acid tert-butyl ester (23)
tert-butyl-6-methoxy-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]-indole-2-carboxylate (0.710 g,
2.34 mmol, 1 eq.) was dissolved in DMF (15 mL) under an argon atmosphere at the room
temperature. The reaction mixture was further cooled down to 0 oC -5 oC for 15 min. To the cooled
reaction mixture, added sodium hydride (60% dispersion in mineral oil, 1.08 g, 4.60 mmol, 1.5
eq.) in batches over the period of 15 min. After complete addition, the reaction mixture was
allowed to stir at room temperature for 30 min before cooling it down again to 0 oC -5 oC. N(Furan-2-ylmethyl)-N-(oxiran-2-ylmethyl)-methane sulfonamide (0.542 g, 2.34 mmol, 1 eq.)
dissolved in 10 mL of DMF was introduced into the reaction mixture drop wise while it was stirring
over an ice bath. After complete addition, reaction mixture stirred at the room temperature
overnight under an argon atmosphere. Work up was done by quenching the reaction with the
saturated solution of ammonium chloride and extracting it with ethyl acetate thrice. The combined
organic layer was washed with water followed by the brine solution. It was then dried over sodium
sulfate and concentrated under vacuum. The crude obtained was then purified by flash
chromatography yielding 0.590 gm of sticky white solid. The compound was used for the
deprotection reaction without analysis by NMR.
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N-Furan-2-ylmethyl-N-[2-hydroxy-3-(6-methoxy-1,2,3,4-tetrahydro-β-carboline-9-yl)propyl]-methane sulfonamide (24)
9-[3-(Furan-2-ylmethyl-methanesulfonyl-amino)-2-hydroxy-propyl]-6-methoxy-1,3,4,9tetrahydro- β-carboline-2-carboxylic acid tert-butyl ester (0.50 g, 0.93 mmol, 1 eq.) was refluxed
with trifluoroacetic acid (0.722 mL, 9.30 mmol, 10 eq.) in DCM (5.00 mL) for 1 hour. The reaction
was quenched by water (10.0 mL), basified by solution of 2 M sodium hydroxide. The aqueous
layer was extracted with DCM thrice. The combined organic layer was washed with water
followed by brine, dried over sodium sulfate and concentrated. Column chromatography afforded
0.170 g of the white solid. 1H-NMR (CDCl3, 500 MHz) δ 7.3 (s, 1H) δ 7.14 (d, J = 9.15 Hz, 1H)
δ 6.92 (d, J= 2.3 Hz, 1H) δ 6.82 (dd, J = 2.85 Hz, J = 9.15 Hz 1H) δ 6.31 (m, 1H) δ 6.17 (d, J =
2.9, 1H) δ 4.52-4.39 (m, 2H) δ 4.04-3.9 (m, 5H), δ 3.84 (s, 3H) δ 3.29 (q, J = 7.45, 1H) δ 3.223.11 (m, 3H) δ 2.79 (s, 3H). 13C NMR (DMSO-d6, 500 MHz) δ 150.08, 143.87, 111.17, 110.65,
110.58, 100.33, 69.05, 68.96, 55.97, 55.92, 51.26, 51.11, 22.31.
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6H-indolo[2,3-b]-quinoxaline (25)
A mixture of isatin (0.6 g, 4.07 mmol, 1 eq.) and ortho-phenylenediamine (0.438 g, 4.07
mmol, 1 eq.) was dissolved in acetic acid (7 mL) in a microwave tube equipped with a septum.
The reaction was microwaved at 150 oC at the power level 160 W for 10 min. The reaction mixture
was neutralized by pouring into an ice-cold saturated solution of sodium bicarbonate (250 mL).
The aqueous layer was extracted with the ethyl acetate thrice. The combined organic layer was
then washed with water followed by brine, dried over sodium sulfate and concentrated. The yellow
color crude such obtained was recrystallized with ethyl acetate. To do so, the solid was dissolved
in boiling ethyl acetate and stored in refrigerator overnight. The yellow needle solid such obtained
was analyzed by 1H NMR. 1H-NMR (CDCl3, 500 MHz) δ 8.89 (s, br, NH), δ 8.48 (d, J = 7.45 Hz,
1H) δ 8.33 (dd, J = 8 Hz, J = 9.15 Hz, 1H) δ 8.11 (dd, J = 6.85 Hz, J = 8 Hz, 1H) δ 7.79 (t, J =
1.85, 1H) δ 7.73-7.67 (m, 2H) δ 7.54 (d, J = 8 Hz, 1H) δ 7.41 (t, J = 6.9 Hz 1H).
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26
N-(3-Benzo[b]carbazol-5-yl-2-hydroxy-propyl)-N-furan-2-ylmethyl-methanesulfonamide
(26)
5H-Benzo[b]carbazole (0.360 g, 1.6 mmol, 1.5 eq) was dissolved in anhydrous 10 mL of
N, N-dimethylformamide under argon atmosphere at room temperature. The reaction mixture was
further cooled down to 0-5 oC for 15 min. To the cooled reaction mixture, added sodium hydride
(60% dispersion in mineral oil, 0.080 g, 3.2 mmol, 1.5 eq.) in batches over the period of 10 min.
Reaction mixture was allowed to stir at room temperature for 1 hour. It was again cooled down to
0-5 oC and N-(Furan-2-ylmethyl)-N-(oxiran-2-ylmethyl)-methane sulfonamide (0.231 g, 0.95
mmol, 1 eq.) dissolved in 10 mL DMF was slowly introduced. After complete addition reaction
mixture was then equipped with condenser and refluxed at 50 oC overnight under argon
atmosphere. Work up was done by quenching the reaction with water and extracting it with ethyl
acetate thrice. The Combined organic layer was washed with brine, dried over sodium sulfate and
concentrated under vacuum. Purification by flash chromatography followed by recrystallization in
ethyl acetate afforded yellow solid. 1H NMR (CDCl3, 500 MHz) δ 8.44 (d, J = 8 Hz, 1H) δ 8.30
(dd., J = 8.05 Hz, J = 8.75 Hz, 1H) δ 7.76 (dt, J = 1.15 Hz, 1H) δ 7.68 (q, J = 7.45 Hz, 2H) δ 7.54
(d, J = 8 Hz, 1H) δ 7.38 (t, J = 6.9 Hz, 1H), δ 7.23 (s, 1H) δ 6.19 (d, J=1.7Hz, 1H) δ 5.13 (s, br.,
OH) δ 4.67 (d, J= 2.3 Hz, 1H) δ 4.55 (s, 2H) δ 4.46-4.43 (m, 2H) δ 3.49 (q, J = 1.15, 2H) δ 2.85
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(s,1H). 13C NMR (CDCl3, 500 MHz) 149, 146, 144, 142, 140, 138, 131, 129.5, 127.3, 121, 119,
111, 110, 70, 51.1, 47.1, 45.3, 38.1.
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CHAPTER 3
INTRODUCTION OF NOVEL SIDE CHAINS

3.1 Introduction
KL001 is a drug which is known for its period altering effect. Remarkably, KL001 is found
to lengthen the circadian period of cryptochrome1-3, which regulates gluconeogenesis4.
Incidentally, the structure-activity relationship of KL001 revealed that the carbazole moiety lacks
critical hydrogen bonding with the essential polar residues in the binding pocket. After the detailed
investigation it was found that the side chain of the KL001 can also be modified for the improved
binding. In the previous chapter, different analogs were synthesized with either a polar moiety in
the ring system or with an extra ring. In this chapter, however, the focus will be on modifying the
linker and the side chain of the KL0015. Furthermore, another focus will be on making different
analogs of KL0442, which recently have shown similar or better activity than KL001.

3.2 Structure-Activity relationship of KL001 side chain
Crystal structure of the KL001 side chain revealed that the furan ring of the side chain
embed itself close to the residues enriched with aromatic and polar substituents5. Particularly,
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tryptophan (W 310) and glutamine (Q 307) are oriented very close to the furan ring. Therefore,
modifying the side chain with the substituents having a propensity to participate in the pi-pi
interactions or in hydrogen bonding will presumably enhance the binding efficiency of the small
molecule5.

Figure 26: Structure-activity of the KL001 side chain: The side chain binding site is enriched
with the aromatic and the polar residues. The furan ring of the KL001, snuggles close to the
tryptophan (W 310) and polar glutamine (Q 307) residues.

While our work was ongoing, Lee et al., had designed a compound named KL044 which
had a different side chain and linker. In KL044, the isopropyl linker of the KL001 was replaced
by an amide linkage, while 2-cyano-6-chloro amine was used as a side chain. Structure-activity
relationship of KL044 had revealed, the amide linker participates in critical hydrogen bonding
interactions with the histidine and serine in the vicinity. While the carbonyl of amide interacts with
the serine (S 394) (3.06 Å) and amino functionality participates in hydrogen bonding interaction
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with 2.35 Å away histidine residue (H 357). Furthermore, the disubstituted benzyl group forms pipi interaction with the tryptophan in the vicinity2.

Figure 27: Structure-activity relationship of KL044: In KL044 the isopropyl linker is replaced
by the amide linkage. The amide linkage participates in important interactions with the polar
residues present in the binding pocket. While carbonyl functionality of the amide linker forms a
hydrogen bond with the histidine 2.3 Å away, the serine residue forms a critical hydrogen bonding
with the NH functionality of amide.

Gaining insights from our detailed outlook on the structure-activity relationship and KL044
interactions, we diverted our focus on to modify the side chains and the linker in rest of the
Zoltowski library. To accomplish that, we used several different side chains with the propensity of
participating in CH-pi interactions and hydrogen bonding.

93

3.4. Design principle of ZL006
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For the sixth compound in the library nitrogen and sulfur containing bicyclic ring systems
were used as a side chain in lieu of methane sulfonamide and furan ring. Additionally, the isopropyl
linker was replaced by an amide linkage.
Benzothiazole was strategically chosen as a side chain for the carbazole in ZL006. A
benzthiazole ring system resembles tryptophan ring, remarkably, two of the tryptophan residues
are present near the side chain binding site (W 310 and W 417). We envisioned the bicyclic
structure of the side chain could participate in π stacking interactions with the two-tryptophan
present, also potentially participate in a stronger hydrogen bond. Most importantly, the
benzothiazole nucleus itself is known to have antimicrobial, antidiabetic and antiviral and antiinflammatory properties6-9. Besides this, the modified amide linker is anticipated to participate in
hydrogen bonding interactions with the neighboring histidine and serine.
In order to synthesize the side chain, 6-benzothiazolamine was treated with
chloroacetylchloride in the presence of triethylamine in DCM at room temperature to obtain Nbenzothiazolchloroacetamide 27. It was then coupled to the carbazole in presence of sodium
hydride in DMF to obtain ZL006 28.
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Scheme 10: Synthesis of ZL006 (35%)

3.5 Design Principle of ZL007
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Imidazo-[2,1-b]-[1,3,4]thiadiazole was used as a side chain for ZL006. Several natural
products having Imidazo-[2,1-b]-thiadiazole moiety10-12 had have been shown to have biological
activity29. We anticipated Imidazo-[2,1-b]-[1,3,4]thiadiazole ring would participate in π-π
interaction with trp-290, on the other hand, the extra benzene ring could snuggle itself deep inside
the cavity and could potentially participate in π- π stacking with W 310 and W 417. Besides this
the linker has just a carbonyl group, which could potentially participate in hydrogen bonding.
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Scheme 11: Synthesis of ZL007 (15%)

The side chain was synthesized by the published synthesis with a few modifications12. 2Thiazolamine was refluxed with 2-bromoacetophenone in ethanol overnight to obtain 2phenylimidazo[2,1-b]-thiazole 28. The cyclized product obtained was then heated with chloroacetyl chloride in 1,4-dioxane to get chloroacetyl derivative of 2-phenylimidazo[2,1-b]-thiazole
29. It was later coupled with carbazole in the presence of sodium hydride and DMF to achieve
ZL007 30.
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3.6 Design Principle of ZL008
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The design principle of another compound in the library was to keep the side chain similar
to KL001 while replacing the linker to amide. The idea was to replace the side chain furan ring
with another heterocyclic five-membered ring system, possibly, with 1,3 azoles. We chose to
introduce 1,3-thaizole as a new side chain owing to its capability of larger pi delocalization than
the corresponding oxazole.
In order to synthesize the side chain, 2-amino-thiazole was treated with chloroacetyl
chloride in the presence of triethylamine in dichloromethane at room temperature to obtain Nbenzothiazolchloroacetamide 32. It was then coupled with carbazole in the presence of sodium
hydride in DMF to obtain ZL008 33.
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Scheme 12: Synthesis of ZL008 (30%)
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3.7 Design Principle of ZL009
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Until now, the compounds synthesized were similar to KL001; modifications were done
either on the scaffold while keeping the side chain same or vice versa. For the 9th compound,
however, we had designed a novel compound in the library, by using one of the new scaffolds and
a side chain. For this compound based on our detailed investigation of structure activity
relationship, we used 5H-Benzo[b]carbazole 5 as a scaffold and benzo-thiazolchloroacetamide 27
as a side chain, attached by an amide linker. We anticipate the four-ring system can possibly mimic
isoalloxazine ring efficiently, unlike carbazole which can only mimic xylene and pyrazine rings of
the whole isoalloxazine ring system. Furthermore, we chose benzo-thiazole side chain because of
its structural similarity with the tryptophan ring system present in the vicinity. The compound was
synthesized by coupling 5H-Benzo[b]carbazole 5 with benzo-thiazolchloroacetamide 27 in the
presence of sodium hydride and N, N-dimethylacetamide under argon atmosphere.
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Scheme 13: Synthesis of ZL009 (24%)
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3.8 Design Principle of ZL010
The last compound in the library was synthesized by keeping in mind that there were
several polar residues present in the side chain binding pocket like glutamine (Q 307).
Furthermore, as mentioned earlier, KL044 having a benzene ring with substituents facilitated
binding and showed better activity than KL001. Therefore, we selected tri-methoxy benzene ring
to make another variant of KL044.
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The side chain 35 was synthesized by treating 3,4,5-trimethoxyaniline with chloroacetyl
chloride in the presence of triethylamine as a base in dichloromethane at room temperature. The
side chain was then linked with carbazole in the presence of sodium hydride in DMF to obtain
ZL010 36.
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Scheme 14: Synthesis of ZL010 (36%)
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3.9 Materials and methods
All the reactions were performed in the dried glassware under an argon atmosphere. All
reagents were purchased from Sigma Aldrich (St. Louis, MO), Fisher scientific (Waltham, MA),
Alfa Aesar (Ward Hill, MA), Chem Impex (Wood Dale, IL) and used as it was received. The
deuterated solvents (CDCl3, DMSO-d6) were purchased from Cambridge Isotope Laboratories
(Cambridge, MA). 1H-NMR and

13

C NMR spectra were recorded using 500 MHz Jeol

multinuclear NMR spectrometer in the Department of Chemistry at Southern Methodist
University. All chemical shifts are reported in the standard notation of parts per million using the
peak of residual proton signals of the deuterated solvent as an internal reference. The coupling
constant units are in Hertz (Hz) splitting patterns are indicated as follows: br., broad; s., singlet;
d., doublet; t., triplet; q., quartet; m., multiplet; dd., doublet of doublets; dt., doublet of triplets.
Microwave reactions were carried out in CEM DiscoverTM. Column chromatography was carried
out on Combi-Flash instrument by using pre-packed silica gel columns
N
S

O
Cl

NH

27
N-Benzothiazol-6-yl-2-chloro-acetamide (27)
6-Aminobenzthiazole (2.70 g, 17.9 mmol, 1 eq.) dissolved in dichloromethane (30.0 mL)
at the room temperature under an argon atmosphere. Triethylamine (3.00 mL, 21.5 mmol, 1.2 eq.)
was introduced at room temperature. The reaction mixture was then allowed to stir over an ice bath
maintained at the temperature of 0 to 5 oC for 15 min. To the cooled reaction mixture, chloroacetyl
chloride (1.7 mL, 21.5 mmol, 1.2 eq.) dissolved in 20 mL of DCM was then added drop-wise over
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the period of 10 -15 min. After stirring it over an ice bath for 15 min, the reaction mixture was
allowed to stir at room temperature overnight. The reaction mixture was concentrated, and the
crude was dissolved in ethyl acetate and water. Aqueous layer was extracted with ethyl acetate
thrice. The combined organic layer was washed with saturated solution of sodium bicarbonate, 5%
hydrochloric acid followed by water and brine. It was then dried over sodium sulfate and
concentrated. Column chromatography of crude solid afforded 2.23 g (55%) of white solid. The
solid was further recrystallized with acetone. which was confirmed by 1H NMR. 1HNMR (DMSOd6) δ 10.58 (s, br., 1H) δ 9.26 (s, 1H) δ 8.49 (d, J = 2.3 Hz, 1H) δ 8.01 (d, J = 12.8 Hz, 1H) δ 7.56
(dd., J = 8.6 Hz, J = 10.9 Hz, 1H) δ 4.27 (s, 2H).
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N-Benzothiazol-6-yl-2-carbazol-9-yl-acetamide (28)
Carbazole (1.00 g, 5.90 mmol, 1 eq.) was dissolved in anhydrous 50 mL of DMF under an
argon atmosphere at room temperature. The reaction mixture was cooled down to 0 oC to 5 oC for
10 min. To the cooled reaction mixture, sodium hydride (60% dispersion in mineral oil 0.359 g,
8.9 mmol) was introduced over the period of 10 min. After complete addition, the reaction mixture
was continued to stir over an ice bath for 15 min followed by at the room temperature for about 1
hour. After 1 hour of stirring, the reaction mixture was again cooled down to 0 oC to 5 oC, and N-
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benzothiazol-6-yl-2-chloro-acetamide (1.35 g, 5.90 mmol, 1 eq.) dissolved in 5.00 mL of DMF
was added to the reaction mixture drop-wise. After that, the reaction flask was equipped with reflux
condenser and allowed to heat at 50 oC overnight under the argon atmosphere. The workup was
done by quenching the reaction with water and extracting it with ethyl acetate (3 x 30 mL). The
combined organic layer was washed with water twice followed by brine and dried over sodium
sulfate, concentrated under vacuum. The white crude obtained was purified by the flash
chromatography. The sticky solid such obtained was crystallized by dissolving in dichloromethane
and then adding n-hexane dropwise till white crystalline solid settled down in the round bottom
flask. The solid was filtered under the vacuum, dried and confirmed by 1H NMR. 1H-NMR (CDCl3,
500 MHz) δ 10.77 (s, br., NH) δ 9.23 (s, 1H) δ 8.48 (d, J = 1.75 Hz, 1H) δ 8.14 (d, J = 7.45 Hz,
3H) δ 8.02 (d, J = 8.6 Hz, 1H) δ 7.58-7.56 (m, 3H) δ 7.41 (t, J = 6.9 Hz, 2H) δ 7.19 (t, J = 8 Hz,
2H) δ 5.3 (s, 2H).
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C-NMR (500 MHz, DMSO-d6) δ (ppm) 167.12, 155.47, 149.81, 141.28,

136.98, 134.85, 126.27, 123.64, 122.81, 120.75, 119.62, 119.25, 112.32, 109.88, 40.37.
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6-Phenyl-imidazo[2,1-b]-thiazole (29)
The mixture of 2-aminothiazole (1.0 g, 99.7 mmol, 1 eq.) and 2-bromoacetophenone (1.98
g, 99.7 mmol, 1 eq.) was dissolved in 20 mL ethanol and refluxed overnight. Ethanol was removed
under vacuum; the crude such obtained was dissolved in water and DCM. The aqueous layer was
extracted with DCM thrice. The combined organic layer was washed with saturated solution of
sodium bicarbonate followed by water and brine. It was then dried over sodium sulfate and
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concentrated. The orange colored solid (1.25 g) obtained was taken for next step without further
purification. 1H-NMR (DMSO-d6, 500 MHz) δ 8.19 (s, 1H) δ 7.90 (d, J = 4.6 Hz, 1H) δ 7.80 (dd,
J= 1.15 Hz, J = 8.6 Hz, 2H) δ 7.34 (dt, J = 7.45 Hz, J =13.7 Hz, 2H) δ 7.23- 7.21 (m, 2H).
O
S

Cl
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2-Chloro-1-(6-Phenyl-imidazo[2,1-b]-thiazol-5yl)-ethanone (30)
6-Phenyl-imidazo-[2,1-b]-thiazole (1.25 g, 6.25 mmol, 1 eq.) was dissolved in 1,4-dioxane
in a two necked 50 mL flask, equipped with condenser and an argon balloon. The mixture was
heated at 70 oC and chloroacetyl chloride (1.5 mL, 18.7 mmol, 3 eq.) was introduced drop-wise.
After complete addition reaction mixture was continued to stir at 70 oC for 15 min. thereafter,
refluxed for 3 hours, reaction was monitored through gas chromatography. The reaction mixture
was cooled down to room temperature and filtered. The residue solid was washed with cold
ethanol. 0.390 g of pale white solid obtained. 1H-NMR (500 MHz, DMSO-d6) δ 8.48 (d, J = 8.6
Hz, 1H) δ 7.61-7.50 (m, 6H) δ 4.30 (s, 2H).
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2-Carbzol-9-yl-(6-phenyl-imidazo[2,1-b]-thiazol-5-yl)-ethanone (31)
Carbazole (0.210 g, 1.26 mmol, 1 eq.) was dissolved in anhydrous 10 mL of DMF under
an argon atmosphere at room temperature. The reaction mixture was cooled down to 0 oC to 5 oC
for 10 min. To the cooled reaction mixture, sodium hydride (60% dispersion in mineral oil 0.075
g, 1.89 mmol, 1.5 eq.) was introduced over the period of 15 min, and then allowed to stir room
temperature for 1 hr. After 1 hour of stirring, it was again cooled down to 0 oC -5 oC, and 2-Chloro1-(6-Phenyl-imidazo[2,1-b]-thiazol-5yl)-ethanone (0.35 g, 1.26 mmol, 1 eq.) dissolved in 5 mL of
DMF was added to the reaction mixture drop-wise. After that, the flask was equipped with reflux
condenser and allowed to heat at 50 oC overnight under argon atmosphere. The reaction was
quenched with water and extracted with ethyl acetate. The combined organic layer was washed
with water followed by brine, dried over sodium sulfate and concentrated under vacuum. The
flash chromatography purification yielded sticky solid which was crystalized by dissolving in
dichloromethane and then adding n-hexane drop wise till white crystalline solid settled down in
the round bottom flask. The solid was filtered, dried and confirmed by 1H-NMR. 1H-NMR (CDCl3,
500 MHz) δ 7.3 (s, 1H) δ 7.14 (d, J = 9.15Hz, 1H) δ 6.92 (d, J = 2.3 Hz, 1H) δ 6.82 (dd, J = 2.85
Hz, J = 9.15 Hz 1H) δ 6.31 (m, 1H) δ 6.17 (d, J = 2.9, 1H) δ 4.52- 4.39 (m, 2H) δ 4.04-3.9 (m,
5H), δ 3.84 (s, 3H) δ 3.29 (q, J = 7.45, 1H) δ 3.11 (s, 2H).
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2-Chloro-N-(thiazol-2-yl)-acetamide (32)
2-Aminothiazole (2.00 gm, 19.9 mmol, 1 eq.) was dissolved in dichloromethane (DCM
30.0 mL) at room temperature under the argon atmosphere. Triethylamine (3.30 ml, 24 mmol, 1.2
eq.) was then introduced at room temperature. The reaction mixture was then allowed to cool down
to 0 to 5 oC for 15 min. Chloroacetyl chloride (1.9 ml, 24 mmol, 1.2 eq.) dissolved in 20 mL DCM
was then dropwise introduced at 0 oC, over the period of 10 min. After stirring it over an ice bath
for 15 min, the reaction mixture was allowed to stir at room temperature overnight. Concentrating
it under vacuum afforded crude, which was dissolved in ethyl acetate and water. Aqueous layer
extracted with ethyl acetate thrice. The combined organic layer was washed with saturated solution
of sodium bicarbonate, 5% hydrochloric acid followed by water and brine. It was then dried over
sodium sulfate and concentrated. A column chromatography of crude solid afforded 1.63 g of
white solid, which was confirmed by 1H NMR. 1H-NMR (500 MHz, CDCl3) δ 7.51 (d, J = 3.45
Hz, 1H), δ 7.05 (d, J = 3.45 Hz, 1H), δ 4.27 (s, 2H).
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2-(9H-carbazol-9-yl)-N-(thiazol-2-yl)-acetamide (33)
Carbazole (0.7 g, 4.1 mmol, 1 eq.) was dissolved in anhydrous 10 mL of DMF under the
argon atmosphere at room temperature. The reaction mixture was cooled down to 0 oC to 5 oC for
10 min. To the cooled reaction mixture, sodium hydride (60% dispersion in mineral oil 0.251 g,
6.3 mmol, 1.5 eq.) was introduced over the period of 10 min, and then allowed to stir room
temperature for 1 hr. After 1 hour of stirring, it was again cooled down to 0 oC to 5 oC, and 2Chloro-N-(thiazol-2-yl)-acetamide (0.740 g, 4.1 mmol, 1 eq.) dissolved in 5 mL of DMF was
added to the reaction mixture drop-wise. Thereafter, the flask was equipped with reflux condenser
and allowed to heat at 50 oC overnight under argon atmosphere. Work up was done by quenching
the reaction with water and extracting it with ethyl acetate. Combined organic layer was washed
with brine, dried over sodium sulfate and concentrated under vacuum. The crude obtained was
then purified by flash chromatography and sticky solid was obtained. 1H-NMR (500, MHz,
DMSO-d6) δ 8.14 (d, J = 7.35 Hz, 2 Ar H), δ 7.54 (d, J =8 Hz, 3ArH), δ 7.48 (d, J = 4.05 Hz, 2 Ar
H), δ 7.48 (t, J = 8.6, 3 Ar H), δ 7.21-7.18 (m, 3 Ar H), δ 5.3 (s, 2H). 13C-NMR (500 MHz, DMSOd6) δ 167.11, 158.14, 141.13, 138.29, 126.36, 122.85, 120.78, 119.77, 114.40, 109.80, 40.36.
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N-(benzo[d]thiazol-5-yl)-2-(6H-indolo[2,3-b]-quinoxalin-6-yl)-acetamide (34)
5a,11a-dihydro-5H-benzo[b]carbazole (0.410 g, 1.87 mmol, 1 eq.) was dissolved in
anhydrous 15 mL of DMF under the argon atmosphere at room temperature. The reaction mixture
was cooled down to 0 oC to 5 oC for 10 min. To the cooled reaction mixture, sodium hydride (60%
dispersion in mineral oil 0.112 g, 2.80 mmol, 1.5 eq.) was introduced over the period of 15min and
then allowed to stir room temperature for one hr. After 1 hour of stirring, it was again cooled down
to 0 oC to 5 oC, and N-Benzothiazol-6-yl-2-chloro-acetamide (0.422 g, 1.87 mmol, 1 eq.) dissolved
in 10 mL of DMF added to the reaction mixture drop-wise. After that, the flask was equipped with
reflux condenser and allowed to heat at 50 oC overnight under argon atmosphere. Work up was
done by quenching the reaction with water and extracting it with ethyl acetate. The combined
organic layer was washed with brine, dried over sodium sulfate and concentrated under vacuum.
The crude obtained was then purified by flash chromatography. The yellow solid such obtained
was recrystallized with ethyl acetate. 1H-NMR (500 MHz, DMSO-d6) δ 10.81 (s, NH), δ 9.25 (s,
1 Ar H), δ 8.46 (d, J = 1.7 Hz, 2 Ar H), δ 8.40 (d, J = 7.4 Hz, 1Ar H), δ 8.01 (d, J = 7.4 Hz, 1 Ar
H), δ 7.77- δ 7.73 (m, 4 Ar H), δ 7.61 (d, J = 8.1 Hz, 1 H), δ 5.43 (s, 2 H). 13C-NMR (400 MHz,
DMSO-d6) δ (ppm) 166.39, 155.45, 149.78, 145.92, 145.51, 140.26, 139.40, 136.79, 134.78,
131.91, 129.60, 127.92, 126.80, 123.57, 122.62, 121.82, 119.22, 117.69, 112.36, 111.24. 44.85.
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2-Chloro-N-(3,4,5-trimethoxyphenyl)-acetamide (35)
3,4,5-Trimethoxyaniline (2.00 gm, 11 mmol) was dissolved in dichloromethane (DCM
20.0 mL) at the room temperature under argon atmosphere. Triethylamine (1.83 mL, 13 mmol)
was then introduced at room temperature. The reaction mixture was then allowed to cool down to
0 to 5 oC for 15 min. Chloroacetyl chloride (1.0 mL, 13 mmol) dissolved in 10 mL DCM was then
added to the reaction mixture drop-wise at 0 oC, over the period of 10 min. After stirring it over
ice bath for 15 min, reaction mixture was allowed to stir at room temperature overnight.
Concentrating it under vacuum afforded crude, which was dissolved in ethyl acetate and water.
Aqueous layer extracted with ethyl acetate thrice. Combined organic layer was washed with
saturated solution of sodium bicarbonate, 5% hydrochloric acid followed by water and brine. It
was then dried over sodium sulfate and concentrated. Flash chromatography of crude solid
afforded 2.6 g of white solid, which was confirmed by 1H NMR. 1H-NMR (500 MHz, CDCl3) δ
8.12 (s, NH), δ 6.82 (s, 2 Ar H), δ 4.18 (s, 2H), δ 3.86 (s, 9 H).
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2-(9H-carbazol-9-yl)-N-(3,4,5-trimethoxyphenyl)-acetamide (36)
Carbazole (0.4 g, 2.39 mmol, 1 eq.) was dissolved in anhydrous 10 mL of DMF under
argon atmosphere at the room temperature. The reaction mixture was cooled down to 0 oC to 5 oC
for 10 min. To the cooled reaction mixture, sodium hydride (60% dispersion in mineral oil 0.144
g, 3.59 mmol, 1.5 eq.) was introduced in portions over the period of 10-15 min. Following
complete addition, the reaction mixture was stirred at room temperature for 1 hour. The reaction
mixture was cooled down to 0 oC to 5 oC and 2-chloro-1-(6-phenyl-imidazo[2,1-b]-thiazol-5yl)ethanone (0.621 g, 2.39 mmol, 1 eq.) dissolved in 5 mL of DMF was introduced dropwise to the
ice cooled reaction mixture. Thereafter, the flask was equipped with reflux condenser and allowed
to heat at 50 oC overnight under argon atmosphere. Work up was done by quenching the reaction
with water and extracting it with ethyl acetate. The combined organic layer was washed with brine,
dried over sodium sulfate and concentrated under vacuum. The crude obtained was then purified
by flash chromatography and sticky solid was obtained. The sticky solid was crystalized by
dissolving in dichloromethane and then adding n-hexane drop wise till white crystalline solid
settled down in the round bottom flask. The solid obtained was filtered and 1H-NMR (500 MHz,
DMSO-d6) δ 10.46 (s, NH), δ 8.14 (d, J = 7.5 Hz, 2 ArH), δ 7.54 (d, J = 8 Hz, 2 ArH), δ 7.41 (t, J
= 1.15 Hz, 2ArH), δ 7.19 (t, J = 1.15 Hz, 2ArH), δ 6.95 (s, 2ArH), δ 5.21 (s, 2ArH), δ 3.67 (s, J =
8 Hz, 6H), δ 3.56 (s, 2H).
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C-NMR (500 MHz, DMSO-d6) δ (ppm) 166.69, 153.30, 141.26,
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135.46, 134.01, 133.97, 126.25, 122.79, 120.73, 119.59, 119.30, 109.85, 109.67, 97.16, 60.71,
60.63, 56.15, 55.94, 46.54, 46.43.
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CHAPTER 4
CELL BASED CIRCADIAN ASSAY

4.1 Introduction
The design principle of all the compounds in the Zoltowski library relies on the careful
investigation of the binding pocket of FAD and the structure-activity relationship of the KL001,
already known for efficient binding and activity. The activity of compounds in the Zoltowski
library as a cryptochrome modulators is tested by a cell-based luciferase activity using a human
osteosarcoma U2OS cell lines stably expressing clock reporter Bmal1-dLuc. To our delight, most
of the compounds of the library showed robust rhythm at all the concentrations tested, and some
of them delay the rhythm at higher concentrations. This chapter discusses the results obtained from
the circadian activity assay of the Zoltowski library. Additionally, a comparative study of the
period shift with that of the KL001is explored.
4.2 Cell Based Circadian Assay
For the circadian rhythm assay, it is crucial to select a cell line which shows a robust
circadian rhythm and can survive longer under confluent conditions, and hence are suitable for
long-term circadian recordings. Notably, several research groups have used human osteosarcoma
U2OS cells for the circadian rhythm assay owing to its robust rhythm. Additionally, the rhythmic
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expression of the clock gene can be monitored noninvasively by using firefly luciferase reporter.
In most of the cells, the clock genes BmaLI and per2 show robust circadian rhythm. Therefore, for
our experiments, we used U2OS cells harboring Bmal-dLuc reporter for monitoring circadian
rhythm following drug administration1,3-5.
4.2.1: Compounds screening

The protocol of compound screening was adapted from Hirota et al5. The compound
screening was done in an opaque bottom 96 well plate. After trypsinization, the cells were
suspended in a batch of culture media and plated 100 µL containing 2000 cells per well. The plate
was then incubated at 37 oC for 2 days (48 hours) to facilitate the cells to reaching full confluency.
The cell growth was monitored by plating a clear bottom plate with the same amount of culture
media in parallel5.
To measure luminescence, the media was replaced with 100 µl explant media containing
HEPES buffer to maintain the optimal pH, a B-27 supplement which synchronizes the cellular
clock and luciferin (1 mM). All the drugs were dissolved in 100% DMSO. The drugs were
introduced into each well by keeping the DMSO concentration constant. KL001 was used a
reference drugs, while some of the wells were only supplied with DMSO. The plate was then
covered with a thin transparent film. The rhythm was then monitored using BioTek cytation 5 plate
reader. The data was collected for the five consecutive days (120 hours) at the temperature 35 oC,
integration time of 14sec, interval time 1 hour 40 min5-7.
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4.2.2 Luminescence Analysis

The luminescence data was analyzed by using R-project computing environment. We used
the R-code analysis algorithm for curve fitting and data display written by Hirota et al. (2008) 1,5.
The raw luminescence data were fit using following equation:
Luminescence = Baseline + mt + Amplitude (e-kt) cos (2𝜋(𝑡 − 𝑃ℎ𝑎𝑠𝑒)/𝑃𝑒𝑟𝑖𝑜𝑑)
The output .txt file was used to plot Luminescence vs Concentration graph by using the Origin
graphing software (Origin Lab 2018).
In addition to observing the rhythm, period lengths were calculated using another R script
non-parametric algorithm JTK_Cycle developed by Professor Karl Kornacker (Ohio state
Univeristy) and Professor John Hogenesch (University of Pennsylvania School of Medicine) 2. The
output file was then used to plot a bar graph of Period vs. concentration. The period length data
was then used to accurately compare the period altering affects with that of KL001.
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Figure 28: Schematic representation of the cell-based circadian study: The potency of the
small compounds to bind with cryptochrome and mimic FAD was tested using BMAL1-dLuc
reporter. Cryptochrome is a repressor of BMAL1 thereby expression of the BMAL1 can be used
to monitor the cryptochrome activity. 96 well plate plated with U2OS cells harboring BMAL1dluc reporter and the luminescence monitoring was done in the biotek plate reader. The output was
analyzed by the R computing environment to observe the period altering effects. The curve fitting
program was used to plot the graph between luminescence vs. time. The JTK cycle was used to
tabulate the period shift behavior of the compounds.

4.3 Results and discussions
The R-computing script was used to analyze the output data obtained from the plate reader.
The curve-fitting was done using the R-script written by Hirota et al. and the output generated with
the script was used to plot the graph Luminescence vs. time1. The bar graph period vs. concertation
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was plotted using the JTK_cycle R-script. Notably, the JTK cycle script was written for the initial
48 -time points2. Therefore, the bar graph only gives the snapshot of the initial 48 time points while
the experiment was done for 120 hours with 73 data points.
4.3.1 Activity of KL001 as a cryptochrome modulator
The activity of KL001 was tested and used as a reference for all small-molecule activity.
KL001 showed an efficient period-altering ability, consistent with the published reports. At low
concentrations, the period was delayed by 1.7 hours. However, the rhythms are completely
abolished at the higher concentrations (8 µM, not shown in the bar graph) indicating that even
though KL001 even though is a potent drug, it could lead to many other clock-related dysfunctions
at the higher concentrations.

Figure 29: Activity of KL001: A) KL001 shifts period in the dose-dependent manner, however
rhythm gets abolished at higher concentration. B) The bar-graph clearly shows a dose-dependent
increase in period shift.
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4.3.2 Activity of ZL001 as a cryptochrome modulator

While we were still developing the cell lines to analyze the potency of the drugs in altering
the cellular rhythm, our collaborator Dr. Carrie Partch UC Santa Cruz compared the efficacy of
ZL001with that of KL001 using live cell luciferase imaging.
The U2OS cell line expressing luciferase reporter gene administered with the drugs at the
different concentrations was tested for period altering effects. ZL001 delayed the period at the
higher concentration without killing the rhythm, at the same time a robust rhythm was observed at
0.1 µM concentration. The reference drug, KL001 (carbazole-scaffold), however, had abolished
the rhythm entirely at the higher concentration (24 µM) (blue). The results depicted ZL001 has a
mild action in delaying the rhythm.
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Figure 30: A comparison of CRY modulators: KL00l (A) and ZL001 (B): X axis: Time (days),
Y axis: Amplitude of luciferase activity. Both the compounds have shown a period shift. At the
higher concentration, KL001 abolishes the rhythm while still maintained with ZL001. ZL001
showed robust rhythm at 0.1 µM (red) concentration (Collaborator: Dr. Carrie Partch UC Santa
Cruz)

ZL001 screening was also conducted in our laboratory by the procedure mentioned earlier.
Our data corroborated the results obtained from the Partch lab. ZL001 was able to maintain the
rhythm at the lower concentration, while delays the period by 1.7 hours at the higher concentration.
On the contrary, KL001 is toxic to circadian function at a higher concentration. The result dictates
that KL001 could potentially have many rhythm related side effects such as sleep deprivation or
other metabolic diseases, while ZL001 might not as rhythm was maintained at a higher
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concentration as well. Also, since ZL001 was able to maintain the rhythm at the lower
concentration, therefore, it could be used to mimic FAD for the biophysical studies.

Figure 31: ZL001 delays rhythm at the higher concentrations: (A) Structure of ZL001 (B) A
graph of luminescence vs. time shows delayed rhythm at the highest concentration (8 µM, teal) in
the experimental condition, a slight shift is also seen at 2.7 µM (light brown). (C) A bar graph
plotted between period vs. concentration shows the period shift from 25.05 (zero drug) to 26.72.
(D) Comparison of ZL001 with KL001: KL001 shows dose dependent increase in the period shift
activity, however abolishes the rhythm at the higher concentration, while ZL001 is active at the
higher concentration and maintains rhythm at all the concentrations used in the experimental
condition.
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4.3.3 Activity of ZL002 and ZL003 as a cryptochrome modulator

A fascinating result was obtained from the ZL002, and ZL003 compounds; contrary to our
initial hypothesis, that only planar compounds will be able to mimic FAD and thereby maintain or
alter the rhythm, both ZL002 and ZL003 altered the period at higher concentrations. Presumably,
the free rotation of the scaffold might allow it to participate in crucial interactions. The extra
nitrogen in both compounds might facilitate hydrogen bonding interactions with the polar residues
in the vicinity. In terms of clock function, ZL002 delayed the rhythm at 0.9 and 2.7 µM
concentrations by 1.7 hours, while ZL003 demonstrated the same behavior at the higher
concentration (8 µM). Incidentally, the extra nitrogen along with a chloro group present in the ring
system of ZL003 are likely facilitating the binding in the initial concentrations.
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Figure 32: ZL002 delays rhythm at the higher concentrations: (A) Structure of ZL002 (B) A
graph of luminescence vs. time clearly shows delayed rhythm at the higher concentrations (0.9
µM pink and 2.7 µM, brown and) in the experimental condition (C) A bar graph plotted between
period vs. concentration shows the period shift of 2.7 hours at 0.9 and 2.7 µM. (D) Comparison
of ZL002 with KL001: KL001 has a better activity at the lower concentration, while ZL002 is
active at the higher concentration.
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Figure 33: ZL003 delays rhythm at the higher concentrations: (A) Structure of ZL003 (B) A
graph of luminescence vs. time clearly shows delayed rhythm at the highest concentration 8 µM
(teal) in the experimental condition. (C) A bar graph plotted between period vs. concentration
shows the period shift from 25.05 (zero drug) to 26.72. (D) Comparison of ZL003 with KL001:
Kl001 has a better activity at the lower concentration, while ZL003 is active at the higher
concentration.
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4.3.4 Activity of ZL004 as a cryptochrome modulator

Pinoline was used as a scaffold as it is a natural biological metabolite of melatonin. Thus,
if it demonstrates physiological effects on the circadian period, it could be an endogenous ligand
of CRY that modulates activity. Remarkably, Pinoline without any side chain attached had a period
altering effects at the higher concentration. Notably the period delay of 1.7 hours was seen at 2.7
and 8 µM concentrations. More importantly, the result indicated that Pinoline is able to bind at the
flavin binding pocket of the CRY and can potentially be tested for its ability as a natural therapeutic
agent.

Figure 34: Pinoline, a natural metabolite shows period altering effects: (A) Pinoline showed
period lengthening effects at higher concentrations, robust rhythm was observed at all the
concentrations indicating the pinoline binding at the FAD binding site. (B) The period lengthening
of about 1.7 hours were observed at 2.7 and 8 µM concentrations.

Intrigued by the results we tested the pinoline scaffold attached with the KL001 like side
chain. The compound showed robust rhythm at all the concentrations used in the experimental
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settings. The period lengthening effect of 1.7 hours were observed at 0.9 and 2.7 µM
concentrations. Particularly, the drug showed robust rhythm indicated by the higher amplitudes in
the fig 35B implying binding ability of the compound. These latter observations are particularly
intriguing. The period lengthening effects are consistent with docking to the FAD binding pocket
to delay CRY degradation, but in contrast to KL001, which suppresses clock function, here we
observe higher amplitude rhythms consistent with enhanced clock activity. Motivated with our
initial results, we plan to test the activity of the compound at the higher concentrations.

Figure 35: ZL004 maintains robust rhythm while delays it at the higher concentrations: (A)
Structure of ZL004 (B) The curve fitting graph depicts robust rhythm was maintained at all the
concentrations with rhythm delaying affects seen at the higher concentrations.(C)The period
delaying effect can be clearly visible at 0.9 µM and 8 µM. (D) Comparison between KL001 and
ZL004: At the 0.9 µM concentration period altering effect of ZL004 is almost similar to that of
KL001.
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4.3.5 Activity of ZL005 as a cryptochrome modulator

In ZL005, benz-quinoxaline was used a scaffold with the belief that it will mimic
isoalloxazine ring efficiently, owing to its four-ring structure. Interestingly, similar to the Pinoline
scaffold, benz-quinoxaline ring system maintained robust rhythm at all concentrations, with higher
amplitudes, as shown in fig 36B. More specifically, the compound demonstrated period
lengthening effects at the higher concentration which clearly indicates binding at the flavin binding
pocket in CRY. The period was significantly delayed by 1.7 hours at the 0.9 µM to 8 µM
concentrations.
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Figure 36: ZL005 sustained robust rhythm and delayed it consistently at the higher
concentrations: (A) Structure of ZL005 (B) A curve fitting graph shows robust rhythm which
gets delayed at the higher concentrations (yellow, teal). (C) A bar graph shows 1.7 hours period
shift from 0.9 µM to 8 µM concentrations (D) Comparison of ZL005 and KL001: The period
delaying effect of ZL005 is almost similar to that of KL001 at the 0.9 µM concentration.

4.3.6 Activity of ZL006 as a cryptochrome modulator

In the sixth compound the side chain and the linker were modified, while carbazole was
used a side chain. The result was particularly intriguing, despite ZL006 retaining KL001 like
carbazole scaffold, ZL006 did not alter the rhythm indicating the compound did not bind the flavin
127

binding pocket. The result indicated that the side chain and the linker also play a critical role in
the efficient binding of a drug. In future, we plan to test this compound for its activity in the higher
concentrations to gauge if the concentration plays any role in the binding ability of the compound.

Figure 37: ZL006 exhibits robust rhythm with no period alteration affects: (A) Structure of
ZL006 (B) A graph of luminescence vs. time shows robust rhythm maintained at all the
concentrations of the drug. (C) A bar graph plotted between period vs. concentration shows no
period shifts. (D) Comparison of ZL006 with KL001: KL001 has a better activity at the lower
concentration, while ZL006 has no period altering effects.
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4.3.7 Activity of ZL007 as a cryptochrome modulator

For ZL007, the carbazole moiety was retained, however, the side chain and the linker had
been changed in ZL007. The compound shows no period altering activity, indicating side chain
might not able be to snuggle close to the tryptophan residues owing to shorter linker used. We
plan not to use this compound for further studies.

Figure 38: ZL007 shows robust rhythm with no period alteration: (A) Structure of ZL007 (B)
A graph of luminescence vs. time shows the rhythm maintained at all the concentrations of the
drug. (C) A bar graph plotted between period vs. concentration shows no period shifts. (D)
Comparison of ZL007 with KL001: Kl001 has a better activity at the lower concentration, while
ZL006 has no period altering effects.
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4.3.8 Activity of ZL008 as a cryptochrome modulator

In ZL008, an amide linker and a thiazole side chain are used as a side chain while keeping
the carbazole scaffold similar to KL044 and KL001. The compound lacks any period altering effect
implying lack of binding at the flavin binding pocket, which is intriguing as carbazole had been
shown to be essential for the efficient binding in the flavin binding pocket. The result of ZL008
along with that of ZL006 indicates the side chain of the compound complements the binding ability
of the carbazole moiety. For instance, in KL044 the electron withdrawing substituents in the side
chain aromatic ring showed to play an essential role in binding. In future, we plan to use
substituents in the side chain moiety (indeed, promising results obtained with the tenth compound
in the library ZL010).
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Figure 39: ZL008 has no period altering effects but robust rhythm: (A) Structure of ZL008
(B) A graph of luminescence vs. time shows rhythm maintained at all the concentrations of the
drug. (C) A bar graph plotted between period vs. concentration shows no period shifts. (D)
Comparison of ZL008 with KL001: Kl001 has a better activity at the lower concentration, while
ZL008 has no period altering effects.

4.3.9 Activity of ZL009 as a cryptochrome modulator

ZL009 is the novel compound in the library, here the benzquinaxaline ring is coupled with
the side chain previously used in ZL006. It was intriguing as the compound substantially
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lengthened the period at the 2.7 µM concentration. Moreover, the result was captivating as the
rhythm is delayed by 3.3 hours similar to that of KL001. Most importantly, the compound not only
shifts the circadian period substantially, but also leads to the amplified rhythms (fig 40B),
particularly, at the 2.7 µM concentration indicating possibly different mode of action.
Notably, the four-membered scaffold ring system was selected such that it can overlap or
mimic the isoalloxazine ring of flavin, while side chain ring system was similar to that of the
tryptophan present in the side-chain binding pocket. The similar scaffold used in ZL005 (discussed
above) with the KL001 side chain was also able to delay rhythm by 1.7 hours, on the contrary the
same side chain used in ZL006 did not alter the rhythm. Further, oscillations were maintained with
significantly enhanced circadian amplitudes. Such affects are particularly intriguing as decline in
circadian period have been associated with aging, and age-related physiological impairment. This
observation enabled us to conclude that possibly, the four-membered scaffold plays a critical role
in a period altering abilities.
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Figure 40: ZL009, a novel compound shows both robust rhythm and the period lengthening
effects: (A) Structure of ZL009. (B) The novel compound maintains robust rhythm at all the
concentrations, period lengthening observed at 2.7 µM. (C) The bar graph shows a significant
delay in the period at 2.7 µM concentration. The period delay is about 3.3 hours similar to that of
KL001 (D) Comparison of ZL009 with KL001: The period lengthening effect at 2.7 µM
concentration is similar to that of KL001.
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4.3.10 Activity of ZL010 as a cryptochrome modulator

The tenth compound in the library was synthesized with the insights taken by KL044. The
structure-activity analysis of KL044 indicated that the substitutes present in the side chain affects
the binding efficiency of the drug. In ZL010 polar substituents are attached in an aromatic side
chain with an amide linker and a carbazole scaffold. It was intriguing that the compound
demonstrates considerable period shifts of 1.7 hours at the higher concentrations but results in
ablation of circadian amplitude. Mechanistically, these results are consistent with those observed
for KL001. Combining observations from molecules like KL001, ZL010 (amplitude lowering) and
ZL009/ZL004 (amplitude enhancing) may facilitate greater understanding of the complexities of
CRY regulation as it pertains to clock maintenance. The results are captivating, and we plan to use
the compound for the further analysis.
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Figure 41: ZL010 showed robust rhythm at the lower concentration, while period
lengthening effects at the higher concentration: (A) Structure of ZL010 (B) A graph of
luminescence vs. time shows a delayed rhythm at the higher concentrations 2.7 and 8 µM of the
drug. (C) A bar graph plotted between period vs. concentration shows period shifts by 1.2 hours
(D) Comparison of ZL010 with KL001: KL001 has a better activity at the lower concentration,
while ZL010 showed period lengthening effects at the higher concentration.

4.4 Conclusion
Although further studies are required, based on our results, we can safely conclude that
scaffold plays a critical role in the period altering effects. To our delight, the hypothesis of
introducing polar interactions in the isoalloxazine binding site proved to be essential for the
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efficient binding. Notably, the introduction of polar moieties in the scaffold was able to maintain
robust rhythm at the lower concentrations, while some of them like ZL001, ZL004, ZL005 showed
period altering effects at the higher concentrations. To rationalize the finding, the four-membered
ring system altered the period similar to that of KL001.
Furthermore, substituents present in the side chain aromatic ring system facilitate the
period lengthening effects. For instance, in the Zoltowski library none of the heterocyclic side
chain used were able to alter the period. However, the trimethoxybenzene side chain delayed the
rhythm by 2.7 hours. It was intriguing that the tryptophan like side chain used in the ZL006 with
the KL001-like carbazole scaffold depicted no period altering effects, whereas the same side chain
in ZL009 with the benz-quinoxaline ring system showed activity similar to that of KL001.
Even though none of the compounds in the Zoltowski library was able to delay the rhythm
like KL001, but interestingly none of them had utterly killed the rhythm. Some of the compounds
in the library can be used for biophysical studies of the signaling mechanism of the cryptochrome.
With these results in hand, we plan to synthesize different analogs of the four-membered
ring scaffold with the polar side chain linked with an amide linker. Moreover, the compounds
which have shown period altering activity, we plan to test their activity at the higher
concentrations. Additionally, we plan to perform degradation assays to determine the toxicity of
these drugs.
4.5 Long-term goals
The circadian clock is the prime determinant of all the physiological behavior, given that
most of the clock related dysfunctions are chronic hence specificity of the drugs is required to
avoid the potential side effects. The long-term goal of this research is to design the site-specific

136

drugs for the critical circadian proteins and individual interactions. Phenotype-based screening of
FDA approved chemical library (LOPAC) had led to explore several small molecules having a
therapeutic effect such as KL0014,8-11. Since the circadian clock is so intricate a target-based drug
design is needed to avoid fatal side effects. For instance, mammals have two cryptochromes CRY
1 and CRY2. Since only CRY 2 has been found to be associated with breast cancer,11 therefore,
site-specific CRY 2 inhibitors could eliminate the off-target effects and thereby the side effects.
Furthermore, the research can be extended to target individual interactions such as cryptochrome:
androgen receptors which are associated with prostate cancer. Other significant interactions exsit
such as CRY:myc, CRY:HIF112.
In recent years, X-ray crystallography has provided a vast platform for the site-specific
drug designing. A high-resolution crystal structure of a protein or a protein complex can provide
better insight into the binding pocket; thereby a site-specific drug can be designed. As we saw
earlier, KL001 was found to be a potent drug out of several LOPAC screened, but on analyzing
the crystal structure of CRY2 in complex with KL001 or with FBXL3, they were able to determine
the mechanistic basis of drug action. Crystal structure revealed the information about the binding
site which led the same group to synthesize yet another potent drug KL044.
The long-term goal of our laboratory will be getting the crystal structure of the proteins,
and individual complexes and from that follow the site-specific drug designing strategy.
4.6 Materials and methods
All the cell culture flasks and 96-well plate were ordered from Fischer Scientific. The U2OS cells
harboring Bmal-dLuc reporter was obtained from ATCC (The American type culture collection).
All the reagents Dulbecco’s Modified Eagle Media (DMEM) composed of L-glutamine, HEPES,
sodium bicarbonate. (Gibco 21063029), fetal Bovine Serum (FBS) and antibiotics
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(penicillin/streptomycin, 100U/ml), luciferin, 2% B27 were ordered from Fischer scientific until
otherwise reported.
4.6.1 Cell Culture

Composition of Medium: (Adapted from Hirota and Kay method).
A sincere thanks to Samuel G. Weber for the media preparation and cell plating before every
experiment.
Culture media:
DMEM (high glucose, no phenol red)
10% FBS
100unit/ml Penicillin and 100ug/ml
streptomycin
1mM Sodium pyruvate

450 mL
50 mL
5 mL
5 mL

Explant media:
DMEM (high glucose, no phenol red),
containing 100unit/ml Penicillin and
100ug/ml streptomycin, HEPES, 1mM
Sodium pyruvate
2% B27
Gentamicin
Luciferin

12 mL

2 µL (added just before the experiment)
0.1 mg/mL (added just before the experiment)
1 mM (added just before the experiment)

U2OS cells harboring Bmal-dLuc reporter were maintained in the culture media at 37 oC.
After trypsinization of the cells, they were seeded in the culture media at the density of 2000
cells/well in an opaque 96-well plate and incubated at 37 oC for two consecutive days for allowing
U2OS to reach to the highest confluency. At the same time, a transparent 96-well plate was seeded
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to monitor the cell growth under the microscope. After two days of incubation, the media was
replaced by an explant media containing B-27 supplement to reset the clock of the cells. The
explant media was also supplemented with luciferin.
4.6.2 Drug Screening
All the drugs were dissolved in DMSO. The drugs were introduced in each well by keeping
the DMSO concentration same. KL001 was used as a reference drug, while some of the wells were
only supplied with DMSO to observe the effect of the neat DMSO. The plate was then covered
with a thin transparent film. The rhythm was monitored using BioTek Cytation 5 plate reader. The
data was collected for the five consecutive days (120 hours) at the temperature 35 oC with the
integration time of 14 seconds and interval time of 1 hour 40 min. The data obtained was used for
the curve fitting data analysis using R programming script.
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CHAPTER 5
LOV DOMAIN PROTEIN LKP2 IN A. THALIANA AND B. RAPA

5.1 Introduction
Plants being sessile have developed robust sensory mechanisms to gauge the surrounding
environment and adapt to facilitate their growth and development. Out of all environmental cues,
light is the most important source which plants sense to dictate the developmental process1. Plants
not only use light for the photosynthetic process but also to regulate several developmental and
metabolic processes such as photoperiodic flowering, hypocotyl elongation2, stomatal opening3,
and phototropism4,5, and chloroplast movement6. In order to do so, plants employ several
photoreceptor proteins which sense broad spectrum of light. The major classes of photoreceptors
in plants are the blue light photoreceptors, phototropins and cryptochromes, and the red/far-red
photoreceptors phytochromes7,8. All photoreceptors can sense various wavelength and intensities
of light and assist the plant in adjusting to the surrounding environment.
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Figure 42: Different photoreceptors in the plant sense light and regulate several physiological
processes

All these photoreceptors are well studied at the molecular level for their role in regulating
plant physiological processes9. Incidentally, in the year 2000 a new kind of the blue light
photoreceptor family named the ZTL family was identified in Arabidopsis thaliana. The ZTL
family in A. thaliana includes three members: Zeitlupe (ZTL), flavin binding kelch repeat F-box1
(FKF1) and LOV kelch protein2 (LKP2)10,11. All these proteins belong to the LOV domain
superfamily of blue-light photoreceptors. The members of ZTL family were found to work in
concert to measure the day length and hence to determine the flowering time and to regulate the
other circadian processes12.To date, the function of ZTL10,15,18 and FKF110,16,17 is well studied in
A. thaliana. However, not much is known about the function of the third member of the family
LKP2. This chapter will mainly focus on characterization and understanding the photocycle of
LKP2 in A. thaliana. In addition, we extend our research to study the important circadian rhythm
proteins in the Brassicaceae family specifically Brassica rapa, which is an essential agricultural

143

crop that includes turnip, Napa cabbage, Chinese cabbage etc. Since circadian rhythm controls
several developmental processes, studying crucial circadian protein in important agricultural crop
can potentially impact the agricultural industry19.
5.2 LOV Domain
LOV (Light Oxygen Voltage) domain are blue light photoreceptors, originally discovered
in the plant phototropins. LOV proteins function as a subset of the Period-Aryl hydrocarbon
receptor nuclear translocator-Singleminded (PAS) domain superfamily, where LOV domains noncovalently binds the flavin cofactors (FAD or FMN) as a photo-responsive element10,13,14. The
PAS fold consists of 5 antiparallel beta strands 2-1-5-4-3 flanked by a series of four a-helices on
one side of the face termed as “A face”. The A-face acts as the photoreceptor core as it binds with
the flavin cofactor within a cavity formed by typical a-helices and β-strands arrangement. The B
face consists of the other side of the beta strands and are typically involved in protein:protein
interactions in PAS and LOV domain proteins. The primary characteristic of LOV proteins are
dictated by their flavin chemistry, which plays an important role in determining the activity and
signal transduction landscape of LOV domain proteins20,21. In Arabidopsis thaliana, LOV domain
proteins like Zeitlupe (ZTL), flavin binding kelch repeat F-box1 (FKF1) and LOV kelch protein2
(LKP2) employ small molecule flavin chemistry to measure the day length and hence determine
the flowering time and regulate the other circadian processes18.
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Figure 43: Schematic diagram of PAS domain fold: PAS domain is composed of 5 antiparallel
β sheets (green arrows) flanked by on one side series of four alpha helices (pink cylinders).

Figure 44: Crystal structure of the Zeitlupe exhibiting a typical PAS fold.
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5.2.1 Flavin chemistry

The photocycle of the LOV domain is chiefly directed by the small molecule cofactor
flavin adenine dinucleotide (FAD) or flavin mononucleotide (FMN). Flavin chemistry is further
modulated by the neighboring group interactions or steric constrains in the spatial environment,
and ultimately the kinetics parameters of the protein21,22. Upon light activation, a covalent adduct
is formed between the flavin cofactor and a conserved cysteine residue in the LOV core. The
cysteine residue is present on the Ea region within a conserved GXNCRFLQ motif. With the
formation of flavin-cysteinyl adduct (C4a) a series of electron and proton transfer reactions occur
leading to the protonation at the N5 position of the flavin ring. Protonation relays changes in the
hydrogen bonding network of the protein starting from the flavin binding pocket to the other
regions of the protein affecting inter-or intra-protein interactions. Upon return to the dark, the
adduct state undergoes thermal decay back to its ground state that corresponds to dark state with
lifetimes varying from seconds to days20-24.
Recently, these variations in the photo-adduct lifetimes was shown to be essential for
proper function. For instance, ZTL functions at the day-night transition which is supported by its
relatively short photocycle kinetics with a half-life of 2 hours18. On the other-hand LKP2 has a
relatively long photo-adduct lifetime with a half-life of approximately six days. Therefore, the
photo-adduct lifetime may provide some insight in predicting the biological function of the protein.
5.2.3 LOV photocycle and kinetics

The photo adduct formation reaction can easily be studied in the laboratory setting by
observing the shift in the UV-vis absorption spectra. Notably, in the dark state the LOV domain
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protein shows the characteristic absorption spectra of oxidized flavin with peaks at 450nm and
vibrational bands at 425 nm and 475 nm (Fig. 44C). Upon blue light activation, the isoalloxazine
ring of flavin forms a covalent linkage with the thiol moiety of a conserved cysteine. Specifically,
blue light activation promotes oxidized flavin at the dark state into the singlet excited state, that
undergoes intersystem crossing to form a triplet state. The triplet state, then abstracts an electron
from the cysteine and generates a radical pair. Subsequent radical recombination leads to the
formation of C4a adduct, which can clearly be observed by a single absorption band peak at 390
nm20,25-28.
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Figure 45: Mechanism of the C4a Adduct formation: (A) Upon blue light activation, a
conserved cysteine residue in GXNCRFLQ motif of LOV domain participates in the C4a adduct
formation with the isoalloxazine ring of flavin (B), (C) The conversion of light and dark state can
be monitored by observing the flavin spectra; in the dark state classic flavin peak can be observed
at 450 nm with the two shoulder peaks at 425 and 475 nm. In light state only one peak is observed
at 380 nm. (D) Blue light activation excites flavin to the singlet excited state followed by the triplet
state. Single electron transfer event takes place from the conserved cysteine, which results in the
formation of a radical pair. The reduced flavin generates upon radical recombination.
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5.2.4 Factors affecting LOV photocycle

There are several factors which dictate the cofactor flavin chemistry and thereby the LOV
domain photocycle and the overall structure of the protein. Primarily, there are three factors which
modulate the flavin photochemistry. First and foremost, is the position of cysteine in the dark state
protein where two different conformers have been observed that differ according to the proximity
of the thiol moiety to the C4a position of the isoalloxazine ring. Computational and kinetic studies
indicate that the light state of the protein is stabilized if the position close to the C4a adduct is
favored, whereas the conformer favoring the position further away leads to a less-stable adduct.
Several studies have indicated that introducing residues that sterically bias the cysteine conformer
to one state or the other can tune adduct state lifetime20,23, 29-31.
The second factor that controls the C4a adduct stability involves conformational changes
occurring in the flavin isoalloxazine ring system. C4a adduct formation changes the hybridization
of the C4a position from the planer sp2 to the tetrahedral sp3 hybridization states, which alters
steric contacts to the neighboring residues, mostly on the residues below or above the isoalloxazine
ring system. Thereby, electronic and steric effects of those residues govern the stability of the
adduct. For instance, Zoltowski et al. showed that the stability of the light state adduct was
enhanced when isoleucine was introduced at the flavin re-face in a fungal protein Vivid of
Neurospora crasa.23
The third crucial factor involves hydrogen bonding and the N5th position of the
isoalloxazine ring system of flavin. Deprotonation of the N5 proton has been shown to be ratelimiting in adduct decay. Thus, factors which either stabilize or destabilize the N5 proton directly
modulate the kinetics of adduct decay. For instance, a conserved glutamine (Q) adopts a position
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as such that its amino functionality participates in the hydrogen bonding with the O4 of the
isoalloxazine ring in the dark state. On the contrary, upon blue light illumination; the C4a adduct
forms which changes the environment at the active site, forces glutamine to flip 180o. The “flipped
conformation” of the glutamine adopts a conformation such that now its carbonyl functionality
forms hydrogen bond with the N5th proton, thereby facilitating in proton abstraction. Later in the
chapter, we will observe the effect of glutamine flip in the LOV domain photocycle of the LKP2
protein31,32.

Figure 46: Glutamine Flip: The amino functionality of the glutamine forms a hydrogen bond
with the O4. Upon blue light activation, the C4a adduct formation leads to the change in the
hydrogen bonding pattern. As a result, a conserved glutamine flips and orients in such a way that
the carbonyl functionality of the glutamine forms a hydrogen bonding with the N5H proton.
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5.3 ZTL Family
The Zeitlupe (ZTL) family forms an important subclass of the LOV domain family. They
are the blue light photoreceptors and play a significant role in both the plant circadian clock and
in mediating photoperiodic responses. The ZTL family includes three blue light photoreceptor
proteins: Zeitlupe (ZTL), Flavin bind Kelch repeat 1 (FKF1) and LOV kelch Protein 2 (LKP2). In
contrast to the other LOV domain proteins, these proteins consist of two unique domains F-box
and Kelch repeats. Structurally, the F-box domain is flanked by the photo reactive LOV domain
at the N-terminus and Kelch domains at the C-terminus. The presence of the extra two domains
provides the ZTL family a unique feature from the other LOV domain proteins; while the LOV
domain acts as a photo sensory domain and perceives blue light, the other two domains are
involved in protein degradation and protein-protein interactions. The main function of the F-box
containing protein is to maintain the pace of the circadian rhythm by regulating the time of day for
specific ubiquitination of substrate and consequent degradation. In this manner, the ZTL family
forms a clade of proteins capable of light-dependent targeted degradation1,10,11 33.
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Figure 47: The Schematic representation of domains in ZTL family: ZTL family consists of
F-box domain flanked by the LOV domain at the N-terminal and six Kelch repeats at the Cterminal. LOV domain participates in photoactivation, while both F-box and kelch repeats take
part in ubiquitination process.

All three members of the ZTL family are known to work in concert to maintain the
circadian rhythm and photoperiodic flowering. The current model of the ZTL family is as follows:
During dawn blue light activated LOV domain favors Zeitlupe (ZTL) to form a complex with
Gigantea (GI), the complex dissociates in dusk and the F-box domain of the ZTL complexes with
TOC1 (Timing of Cab 1) and PRR5 and to them for proteasomal degradation. FKF1 on the other
hand, forms a complex with Gigantea and regulates photoperiodic flowering by repressing CDF
(Cyclin Dof factor)11,18. All these protein target, directly alter gene transcription, thereby
modulating clock-controlled gene transcription in a light-dependent manner.
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Figure 48: A schematic representation of circadian and photoperiodic clock in A.thaliana.
ZTL forms a complex with Gigantia (GI) during the day time, at the same time FKF1 forms a
complex with GI and degrades Cyclin Dof Factor (CDF), thereby regulate photoperiodic timing.
At night, ZTL gets dissociated with GI and degrades TOC1 and thereby represses the transcription
of circadian genes. The symbol
indicates degradation pathway. (Adapted from: Pudasaini et
al. Biochemistry 2013, 52, 7150-7158)

Although specific functions of ZTL and FKF1 are known, the function of LKP2 is still
ambiguous. Notably, research has shown LKP2 is an important member of the ZTL family and
plays a crucial role in maintaining circadian rhythm. Shultz et al. (2001) first identified LKP2 gene
and have shown LKP2 functions either within or very close to the circadian oscillator in A.
thaliana. In the study they found overexpression of LKP2 led to several arrhythmic phenotypes
for the multiple circadian outputs both in constant dark and light34. Incidentally, the overexpressed
mutant showed loss of photoperiodic flowering time and long hypocotyls. Moreover, another
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independent study by Baudry et al. found that ztl fkf1 lkp2 triple mutant showed weaker circadian
rhythm than the double mutant ztl fkf1 suggesting LKP2 participates in the circadian rhythm
process12. Mechanistically, what differentiates LKP2 from the other members of the ZTL family
is unknown.
Herein, we investigated the thermal photocycle of Arabidopsis thaliana. We anticipate the
kinetics study can provide important clues about the active site configuration that could possibly
decipher the actual role of LKP2 in the plant circadian clock and what differentiates its function
from ZTL and FKF1. Further, we will extend our research to study LKP2 protein of Brassica rapa,
where due to gene duplication, roles of ZTL and FKF1 is undertaken by set of three LKP2.
5.3.1 Arabidopsis thaliana LKP2

The PAS domain of the LKP2 shares 77% amino acid sequence identity with Zeitlupe and
67% identity with FKF134. The sequence alignment of proteins in ZTL family revealed, LKP2
differs with other LOV proteins at the position 153, where both other members ZTL and FKF1 as
well as all other characterized LOV proteins contain a conserved glutamine residue at this site. As
discussed earlier in fig 41, a conserved glutamine flip plays an important role in LOV photocycle
and LOV signal transduction and was believed to be indispensable for function.
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Figure 49: Sequence alignment of the ZTL family: Sequence alignment showed LKP2 differs
from ZTL and FKF1 at the conserved glutamine (Q) position instead it has Leucine (L)

In LKP2 the polar glutamine (Q) residue is replaced by a hydrophobic leucine (L) residue.
Importantly, same substitution abrogates function in all other LOV domains. We therefore,
concluded to introduce a point mutation in LKP2 (L153Q) to mutate the leucine residue to the
glutamine observed in all other LOV domains. Presumably, the comparison of the kinetic
photocycle of both wild type and mutant could help us delineating the signaling pathway of LKP2.
5.3.2 Brassica rapa LKP2

Sequence alignment of ZTL family proteins with the F-box harboring LOV domain
proteins of Brassica rapa revealed only proteins with the sequence similarity to LKP2 and no
copies of ZTL and FKF1. Incidentally, evolutionarily, B. rapa has undergone genome duplication
resulting in complete loss of some of the gene and polyploidization of others. Interestingly, in
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Brassica rapa, triplication of LKP2 is observed and it is believed that these additional copies have
undertaken the role of ZTL and FKF136. Importantly, all three harbor the leucine at position 153,
which should lead to inactive proteins.

Figure 50: Sequence alignment of all three LOV domain harboring F-box proteins in
Brassica rapa along with the LOV domain proteins of the ZTL family. The sequence
alingement clearly reveals all the proteins are similar to LKP2 of the A thaliana. Like LKP2,
Instead of conseved glutamine (Q) all the three proteins of B.rapa have leucine (L)

Hitherto plant circadian rhythm studies have been done in A. thalaina which had been a
model organism for the circadian rhythm research. We extended our research and studied thermal
kinetics study of all three LKP2 present in B.rapa termed as BrLKP2-A, BrLKP2-B and BrLKP2C. Sincere thanks to Shital Kale and Shannon Swisher for providing the BrLKP2-C data. The data
reported in Shital Kale’s thesis used wrong temperature values.
5.4 Results and discussions
Reversion of the light state (C4a adduct state) to the dark state (oxidized flavin) was
monitored at time interval of 20 min for several days. The data was plotted between absorbance
vs. time at different temperature ranging from 29-43 oC. Each data set was collected in triplicates.
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The half-life of the protein was calculated by the average of rate constant calculated after data
fitting with an exponential decay equation.
𝑦 = 𝐴1 ∗ exp :−

𝑥
< + 𝑦0
𝑡1

Figure 51: (A) The spectra of LKP2 protein exemplifies the C4a adduct formation. The dark state
(black) at 450 nm with the shoulder peaks at 425 and 475 nm represents oxidized flavin. Blue light
bleaching results in a light state peak (red) representing a C4a adduct formation. (B) Reversion of
the light to the dark state demonstrate first order kinetics as shown by the absorbance band at 450
nm (red) and 478 nm (black).

To better understand the photocycle of the LKP2 and BrLKP2, Arrhenius and Eyring
analysis of dark state recovery was performed and different kinetic parameters such as activation
energy and entropy were calculated.
5.4.1 Thermal kinetics of A. thaliana LKP2

Thermal kinetics studies indicate that compared to other LOV domain proteins, LKP2 has
slower adduct decay rate with the longer half-life (t) of 137 hr., while that of mutant is reduced to
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7 hours. The observation clearly shows the importance of glutamine (Q) in the active site of the
LOV domain proteins. Furthermore, the Eyring and Arrhenius analysis of LKP2 revealed strong
temperature dependence of LKP2 owing to the higher enthalpy of activation (115.9 KJ/mol.).
LKP2 mutant (L153Q), on the contrary showed less temperature dependence due to the low
enthalpy of activation (99.4 KJ/mol.). Notably, the mutation has caused the enthalpy of activation
similar to that of the fast-cycling LOV domain proteins (70-100 KJ/mol.)24.

Figure 52: Thermal kinetics comparison of A. thaliana LKP2 and LKP2 (L153Q) mutant:
A and C: Arrhenius and Eyring plot of LKP2 (16-165). B and D Arrhenius and Eyring plot of the
mutant.
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Table 4: Kinetic parameters of A. thaliana LKP2 and LKP2 (L153Q) mutant
Kinetic Parameters

Wild Type

Mutant

Activation Energy (Ea) (KJ/mol)

115.9

99.4

Enthalpy (DH±) (KJ/mol)

113.3

96.9

Entropy (DS±) (J/mol.K)

31.1

-3.8

t (25 oC)
Rate, K (s-1)

136 hrs.
2.0 x 10-6

7 hrs.
3.6 x 10-5

5.4.2 Thermal kinetics of BrLKP2- B and C
5.4.2a Thermal kinetics of BrLKP2 B
The slow cycling BrLKP2-B has a half-life of 27 hours, while the half-life of the mutant is
reduced approximately by 10-fold to 2.6 hours. BrLKP2 WT shows weak temperature dependence
compared to AtLKP2, due to relatively low activation energy (87.14 KJ/mol. vs. 115.9 KJ/mol.)
that is compensated by an unfavorable entropy (-58.7 J/K vs 31.1 J/K).
The mutant with the half-life of 2.6 hours demonstrated activation energies within the range
of fast cycling LOV proteins (70-100 KJ/mole). Moreover, Eyring analysis indicated the low
enthalpy of activation is compensated by a large unfavorable entropy (-67.49 J/K)
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Figure 53: Thermal kinetics of BrLKP2-B and BrLKP2 (L149Q) mutant: A and C:
Arrhenius and Eyring plot of BrLKP2-B (29-165). B and D Arrhenius and Eyring plot of the
mutant L149Q mutant

Table 5: Kinetic parameters of B.rapa LKP2-B and B.rapa LKP2-B (L149Q) mutant
Kinetic Parameters
Activation Energy (Ea) (KJ/mol)
Enthalpy (DH±) KJ/mole
Entropy (DS±) J/mol.K
t (at 25 oC)

Wild Type
87.14
84.57
-58.74
27 hours
(measured)
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Mutant
78.14
75.56
-67.49
2.6 hours (calculated)

5.4.2b Thermal kinetics of BrLKP2 C

The kinetics parameters of BrLKP2-C were similar to BrLKP2-B where the half-life of the wild
type was 29 hours (vs. 27 hours of B-variant).
The BrLKP2-C LàQ behaved similar to the mutant of the LàQ mutant of the B variant
with a half-life of 2.5 hours (2.6 hours of B variant). However, the low enthalpy of activation of
the BrLKP2-C mutant was compensated by relatively large unfavorable entropy of activation
(144.22 J/K vs. -67.49 J/K). The data clearly revealed a far weaker temperature dependence,
characteristic of a very low enthalpy of activation compensated by a large negative entropy of
activation.

Figure 54: Thermal kinetics of BrLKP2-C: A and C: Arrhenius and Eyring plot of BrLKP2-C
(29-165). B and D Arrhenius and Eyring plot of the mutant (L149Q).
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Table 6: Kinetic parameters of B. rapa LKP2 and LKP2 (L153Q) mutant
Kinetics parameters

BrLKP2C_WT

Activation Energy
(Ea) KJ/mole
Enthalpy ΔH±
KJ/mole
Entropy ΔS±
J/mole.K
τ at 25 oC
(Hours)

85.76

BrLKP2C_L2Q
Mutant
55.10

88.30

52.58

50.03

-144.22

29

2.5

Based on our studies, we propose LKP2 shows different temperature dependencies which
may allow for temperature compensation, temperature sensing pathways as has been indicated for
other photoreceptor families. Our results indicated At-LKP2 protein demonstrated higher
temperature dependencies compared to both the variants of Br-LKP2 (B and C). Moreover, both
the variants of BrLKP2 (B and C) showed nearly similar temperature dependencies. Notably, the
life time of the adduct decay was longer in the At-LKP2 than Br-LKP2. Furthermore, our studies
corroborate that the invariant glutamine in the LOV domain family is critical for functioning as
significant difference was seen in the lifetime of the LKP2 photocycle when leucine (L) was
mutated to glutamine (Q).
5.5 Materials and methods
Cloning and Protein Purification
The nucleotide encoding LKP2 was obtained from The Arabidopsis Information Resource
(Tair). N-terminal and C-terminal truncated LKP2 construct (16-165) was cloned by PCR
amplification. The PCR products were examined using 1% agarose gel followed by the gel
purification. The constructs were cloned into 6-His parallel vector with ampicillin resistance using
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BamH1 and Hind III restriction sites. LKP2 (16-165) construct was further used to introduce a
L153 Q point mutation using Quick change protocol (Stratagene). Both, LKP2 construct (16-165)
and the mutant (L153Q) sequence were verified by DNA sequencing (Genewiz). Proteins were
expressed in Escherichia coli BL.21(DE3) cells. Cells were grown at 37 °C until optical density
(OD600) reached 0.5, at which the temperature was reduced to 18 °C for 30 min. The protein
expression was induced by 0.2 mM isopropyl thiogalactoside (RPI). After 22 h, the cell pellets
were harvested and stored in 100 mM NaCl, 50 mM Hepes (pH 8.0) 10 % glycerol at 4 °C. LKP2
construct and mutant pellets were purified using Ni-NTA affinity resin (Qiagen) at 22 oC; Washing
and elution of protein was done by 20 mM imidazole and 250 mM imidazole, respectively. His6
affinity tag was cleaved by incubating the eluted protein with 2mg/ml TEV protease enzyme
(Tobacco Etch Virus Protease) overnight. The residual imidazole and the His6-TEV was removed
by buffer exchange followed by another round of affinity purification. The protein was further
purified by size exclusion column (superdex S-200) already equilibrated with the 100 mM NaCl,
50 mM Hepes (pH 8.0) 10 % glycerol buffer.
Cloning and Protein Purification of BrLKP2
The nucleotide encoding BrLKP2A, B and C were obtained from Jin A. Kim from the
Rural Development Agency, Republic of South Korea. Both N and C-terminal were truncated
BrLKP2 construct (29-165) was cloned by PCR amplification. The PCR products were examined
using 1% agarose gel followed by the gel purification. The constructs were cloned into GST
parallel vector with ampicillin resistance using EcoR1 and Not1 restriction sites. A point mutation
of L143Q was introduced using Quick change protocol (Stratagene). Both, the constructs BrLKP2B, C and their mutants (L153Q) sequence were verified by DNA sequencing (Genewiz). Proteins
were expressed in Escherichia coli JM109 cell lines. Cells were grown at 37°C until optical density
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(OD600) reached 0.5, at which the temperature was reduced to 18 °C for 30 min. The protein
expression was induced by 0.2 mM isopropyl thiogalactoside (RPI). After 22 h, the cell pellets
were harvested and stored in 100 mM NaCl, 50 mM Hepes (pH 8.0) 10 % glycerol at 4 °C.
BrLKP2 construct and mutant pellets were purified using glutathione affinity resin
(Qiagen) at 22 oC. Washing was done by 100 mM NaCl, 50 mM Hepes (pH 8.0) 10 % glycerol.
The GST tag was cleaved by incubating the eluted protein with 2 mg/mL TEV protease enzyme
(Tobacco Etch Virus Protease) overnight. The cleaved protein was eluted in the buffer, another
round of nickel-nitriloacetic acid chromatography was done to remove His6-TEV followed by a
final purification with a superdex S-200 size exclusion chromatography.
UV-Vis Absorbance Spectroscopy and Kinetics:
UV−visible absorbance spectroscopy of LKP2 16-165 and LKP2 (L153Q) 16-165 were
conducted either on Agilent 8453 spectrophotometer or BioTek plate reader. Spectra for thermal
reversion was recorded at the concentrations of 50 µM. All kinetics experiments were performed
by illuminating the protein samples with a flood light source (150 W), while incubating the protein
on ice to populate the light state. Each data set were done in triplicates to check the consistency in
the data collection. After illumination of the dark state protein, spectra were recorded at different
times until the absorbance reached to the saturation state. Thermal reversion kinetics of LKP2 and
BrLKP2 constructs were obtained at the absorbance of 450 nm and 478 nm with respect to time.
Data fitting was done using mono- and bi-exponential equations as required to extract
kinetic parameters. All time constants were reported as 1/ k adduct scission that was averaged
between the values obtained at 450 and 478 nm. All other kinetics parameters were calculated
based on Arrhenius and Eyring equation.
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APPENDIX I
CRYSTAL STRUCTURE OF CRYTOCHROME LIKE ALGAL PROTEIN: OTCPF1

A1. Introduction
Light is the prime source of energy in all forms of life ranging from the simplest organisms
like photosynthetic algae to the mammals. Algae are the supreme producer of the biomass on the
Earth and contribute significantly to the global production and biogeochemical cycling. Just like
plants, photosynthetic algae utilize light for the growth and development processes. Light dictates
essential physiological process in algae such as photosynthesis, gene expression, and circadian
clock entrainment. Recently, several algal genome sequences including diatoms and green algae
(such as Ostrococcus tauri and Chlamydomonas reinhardtii) were made available. Interestingly,
photoreceptors such as red and blue light photoreceptors including cryptochromes and photolyase
type of photoreceptors were found. Phylogenetic analysis of Ostrococcus tauri revealed 5 genes
belonging to cryptochrome photolyase family (CPF) family.
The cryptochrome photolyase family1 (CPF1) family consist of the proteins of varied
functions. The family consists of three major groups of the proteins: the CPD (cyclobutane
pyrimidine dimer) photolyase, (6-4) photolyases and the cryptochrome. While both CPD
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photolyase and (6-4) photolyases participate in ultraviolet-induced DNA repair activity, the
cryptochrome does not participate in the DNA repair activity. The cryptochrome acts as a
photoreceptor protein in plants and insects, whereas in animals it works in a light-independent
manner and is a part of the core circadian clock. Interestingly an algal protein OtCPf1 has been
found to possess dual functionality; not only it showed the (6-4)-photolyase activity but also
interacted with CLOCK and BMAL1 characteristic of the mammalian circadian clock.
We particularly became interested in studying the otcpf1 as it possesses the characteristic
of the mammalian cryptochromes. Since photosynthetic alga show robust circadian rhythm and
alga being a unicellular or simplest cell to study the function and signaling mechanism of the
critical circadian proteins can easily be understood.
A1.2 Protein Crystallization

To obtain better insights of the cryptochrome and its signaling mechanism, we crystalized
deletion mutant of OtCPf1 (D 258-293). We deleted the disordered loop from the otcpf1 full length,
to facilitate the protein to crystalize. Hanging drop method was used to crystalize the protein after
purification in the reduced environment in the presence of DTT (1,4-Dithiothreitol).
Initially, protein screening was done at the room temperature in the dark room using
Hampton crystal screens. However, multitude of nucleation centers were formed and as a result
the crystals appeared were not big enough to give a conclusive data after X-ray crystallography.
All our efforts to avoid getting multiple nucleation centers such as changing pH of the buffer,
reducing the precipitant or the protein concentration did not yield better results. Delightfully,
purification and crystallization procedures done at the lower temperature (4 oC) was able to reduce
the number of nucleation centers in each well yielding two or three crystals per well. X-ray
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crystallography study of the crystals provided us 2.9 Å of data set, which we are in the process of
solving.
A2 Results and discussion
Currently, the unfinished data has provided us some insights of the protein structure. The
comparison of the OtCPf1 protein with the cryptochrome-2 revealed the presence of similar
residues in the active site. Moreover, the residues which are essential for the KL001 binding at the
active site (as discussed in chapter 2) are also present (Fig 46 C). We anticipate our success in
crystallizing otcpf1 will open new avenues to study the drug binding in the cryptochrome binding
site. Possibly, will assist in site-specific drug designing and in the biophysical studies.
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Figure 55: Structure of OtCPf1 (A) The cartoon structure of OtCPF1 (B) FAD bound in the
FAD binding pocket of OtCPF1. (C) Residues which were found to be essential for the KL001
binding are present and labled. (D) Side chain of the FAD snuggle close to the tryptophan and
glutamine residues.
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A3 Future direction.
As OtCPf1 has a structural similarity with the mammalian cryptochrome, therefore, we
plan to crystallize the protein with one of the drugs from the ZL library and get the crystal structure
to study the structure-activity relationship. In addition, we plan to use the Otcpf1 protein for
determining the binding efficiency of the small molecules.
A4 Materials and methods
A4.1 Cloning and Protein Purification
The codon optimized full length Otcpf1 were cloned into pGST parallel vector. The
sequence was verified by DNA sequencing (Genewiz). Cells were grown in Luria-Bertani (LB)
medium at 37 oC, until the OD600 reached to 0.5. The temperature of cells was decreased to 18oC
for 45 min. Protein expression was induced by 0.2 mM of isopropyl thiogalactoside (IPTG). Cell
harvesting was done after 22 hours; cells were pelleted and were stored in 50 mM Tris (pH = 7.4),
100 mM NaCl and 10% glycerol.
OtCPf1 was purified with glutathione affinity resin (Qiagen) at 4 oC. Bound protein
OtCPf1-GST in column was treated with 2 mg of TEV protease per milliliter of resin overnight at
4 oC. 20 mM of Imidazole was added to the eluted protein; an additional round of Ni-NTA
chromatography then cleaved His6-TEV. Protein was then incubated with 5 mM Dithiothreitol for
30 min at 25 oC to avoid oligomerization. The size Exclusion Chromatography was then used to
further purify protein using 50 mM Tris (pH = 7.4), 100 mM NaCl and 10% glycerol. Crystal tray
were set using protein concentration of 6 mg/mL, 9 mg/mL at room temperature and at 4 oC.
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Structural Analysis:
Initially, OtCPf1 deletion mutant crystals were obtained with the reservoir solution
containing 0.1 M HEPES sodium (pH=7.5) 1.4 M sodium citrate tribasic dihydrate in dark at room
temperature at the 6 mg/mL and 9 mg/mL concentration. Crystals were also obtained at 4 oC with
the reservoir solution of 1.6 M Sodium citrate tribasic dihydrate pH 6.5 (Hampton screen in HR2112)
Diffraction data were collected at the F1 beamline at the Cornell energy synchrotron source
(CHESS). Data was collected with 20% ethylene glycol as a cryoprotectant. The diffraction data
obtained were scaled and reduced in HKL2000. The phase information was obtained by molecular
replacement with phaser and phenix and a search model of photolyase (Protein Data Bank code
(3FY4). The iterative rebuilding cycle was completed in coot and refinement was achieved by
Phenix.
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APPENDIX II.
SCANNED 1H AND 13C NMR SPECTRA
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